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keted kinase inhibitor, has been shown in several studies to be

CROSS-REFERENCE TO RELATED
APPLICATION

This application claims the benefit under 35 U.S.C.
S119(e) of U.S. Provisional Application No. 61/377,871,
filed Aug. 27, 2010, which is hereby incorporated by refer
ence in the present disclosure in its entirety.
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BACKGROUND

1. Field

The present disclosure relates generally to piperazinylpy
rimidine analogs and uses thereof. The invention also relates
to methods of preparing these compounds.

15

1542–1547; Wood, E. R. et al. Cancer Research 2004, 64,

2. Related Art

The human kinome, represented by 518 kinases, is a
widely investigated protein family on biological, chemical,
and clinical levels. Protein kinases are involved in the major
ity of signal transduction pathways regulating the cell
machinery of Survival, proliferation, and maintenance.
Accordingly, several pathological abnormalities are corre
lated with aberrations in the operational integrity and accu
racy of certain kinases inside the cell, making kinases attrac
tive targets for treating, diagnosing, and establishing
personalized therapies of various disorders such as different
malignancies, neurodegenerative disorders, rheumatoid
arthritis, autoimmune diseases, and others (Eglen, R. M.;
Reisine, T. Assay and Drug Development Technologies 2009,
7, 22-43; Eglen, R. M.; Reisine, T. Expert Opinion on Drug
Discovery 2010, 5, 277-290; Parikh, K. Peppelenbosch, M.
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Settleman, J. Journal of Clinical Oncology 2009, 27, 5650
5659).
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Kinase inhibitors, either Small molecules or monoclonal

antibodies, represent a class of molecularly targeted antican
cer agents; approximately 14 kinase targeting agents have
earned FDA approval during the last two decades as either
anticancer or antiangiogenic agents. In comparison, not as
many agents targeting other cancer-relevant families such as
Bcl-2 proteins, histone deacetylases, and phosphatases, have
gained regulatory approval. Furthermore, the discovery, pre
clinical, and clinical development of novel kinase inhibitors
currently are the focus of pharmaceutical industry research
efforts, especially those seeking novel and effective cancer
controlling agents (Selzer, E. Expert Review of Clinical Phar
macology 2010, 3, 161-163).
The design of selective kinase inhibitors has proven to be
challenging due to the conservation of the ATP binding site,
targeted by most inhibitors, among different kinases. Several
design strategies, both computer assisted, bioinformatics
aided, and structure based, have been implemented to tailor
more selective kinase inhibitors against a Subset of kinases or
certain kinase subfamilies (Eglen, R. M.; Reisine, T. Expert
Opinion on Drug Discovery 2010, 5,277-290; Akritopoulou
Zanze, I.: Hajduk, P. J. Drug Discovery Today 2009, 14,
291-297; Bogoyevitch, M. A.; Fairlie, D. P. Drug Discovery
Today 2007, 12, 622-633; Huang, D. et al. Bioinformatics
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6652-6659). However, it is unjustified, according to several
published reports, to claim that every type-I kinase inhibitoris
promiscuous and that every type-II inhibitor is selective
(Karaman, M. W. et al. Nature Biotechnology 2008, 26, 127
132). Additionally, a given small molecule kinase inhibitor
usually tends to recognize a given conformational ensemble
of its target kinase(s) that may happen to differentially belong
to either the active and/or the inactive state. That is to say that
a type-I inhibitor, for example, may still bind to the inactive
form of its kinase but with less affinity than with the active
state. Considering another dimension of variability, some
inhibitors interact potently with both the active and the inac
tive forms of their targeted kinases. For example, MK-2461 is
able to bind with considerable potency to both the phospho
rylated and the unphosphorylated forms of c-MET kinase
with a measured binding constant (Kd) of 4.4 and 27.2 nM
respectively (Pan, B. S. et al. Cancer Research 2010, 70.
1524-1533). Contrary to the behavior of MK-2461, Sunitinib
exhibits a strong differential selectivity towards the unacti
vated wild-type KIT versus the active form (Gajiwaia, K.S. et
al. Proceedings of the National Academy of Sciences of the
United States of America 2009, 106, 1542–1547). Generally
speaking, the clinical fact that both lapatinib and Sunitinib
have successfully helped save or at least improve the life
quality of certain cancer patient populations illustrates that,
when it comes to kinase inhibitors, it is arguable that selec
tivity is always a virtue and non-selectivity is a constant
drawback. In fact, Some kinase modulating agents may
achieve better clinical outcomes via targeting several kinases
whereas others can cause troublesome side effects even while
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2009, 26, 198-204; Kirkland, L.O.; McInnes, C. Biochemical

Pharmacology 2009, 77, 1561-1571; Smyth, L.A.: Collins, I.
Journal of Chemical Biology 2009, 2, 131-151; Aronov, A.M.
et al. Journal of Medicinal Chemistry 2008, 51, 1214-1222;
Knight, Z.A.; Shokat, K. M. Chemistry and Biology 2005, 12,
621-637). One successful example is lapatinib, which is
known to be a selective inhibitor against many wild-type and

a highly promiscuous agent capable of interacting with more
than 15% of kinases with a very high affinity (Kd-100 nM)
(Morphy, R. Journal of Medicinal Chemistry 2010, 53, 1413
1437; Karaman, M. W. et al. Nature Biotechnology 2008, 26,
127-132). The selectivity of lapatinib compared to the pro
miscuity of Sunitinib is usually rationalized by the observa
tion that lapatinib is a type-II inhibitor which binds to the
ATP-binding site as well as penetrating the adjacent allosteric
binding site of its target kinases, whereas Sunitinib is a type-I
inhibitor that binds mainly to the ATP-binding site of several
kinases (Gajiwaia, K. S. Proceedings of the National Acad
emy of Sciences of the United States of America 2009, 106,
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being selective (Petrelli, A.; Giordano, S. Current Medicinal
Chemistry 2008, 15, 422-432). Moreover, small molecules
generally and kinase inhibitors specifically are usually pro
miscuous hitters of several protein families and that could be
why not all potent kinase inhibitors survive through the drug
development process (McGovern, S. L.; Shoichet, B. K. Jour
nal of Medicinal Chemistry 2003, 46, 1478-1483).
The phenomenon of kinase inhibitors being mostly non
selective has inspired the founding of several high-through
put kinase profiling screens in order to determine intended as
well as off-target kinases affected by a given kinase inhibitor
(Karaman, M. W. et al. Nature Biotechnology 2008, 26, 127
132; Fedorov, O. et al. Proceedings of the National Academy
of Sciences of the United States of America 2007, 104,20523
20528; Ma, H. et al. Expert Opinion on Drug Discovery 2008,
3, 607-621). These screens have been used to investigate the
kinase binding potential or the functional inhibitory activity
of a given Small molecule against a large panel of kinases and
thereby have facilitated uncovering some of the structural
features relevant to promiscuity. However, it is now appreci
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ated that a given kinase may be more promiscuous than
another even with a difference of only a few amino acids
because the conformational space of the kinase depends on
structural features at the primary, secondary, and tertiary lev
els (Bamborough, P. et al. Journal of Medicinal Chemistry
2008, 51, 7898-7914). A deeper understanding of protein
kinase promiscuity in cases where there are correlations
between the ATP-binding sites of certain subfamilies that are
not closely related based on sequence similarity is needed
(Kinnings, S. L.; Jackson, R. M. Journal of Chemical Infor
mation and Modeling 2009, 49,318-329). Resistance through
several mechanisms, most frequently single point mutation,
has been developed by cancer cells towards several kinase
inhibitors; those who target proliferation and/orangiogenesis
including both selective and non-selective kinase inhibitors
(Christoffersen, T. et al. European Journal of Pharmacology
2009, 625, 6-22; Martin, A. P. et al. Cancer Biology and
Therapy 2010, 8, 2084-2096: Pages, G.; Grepin, R. Journal of
Oncology 2010).
Thus, there remains a need for novel protein kinase inhibi
tor compounds with desirable pharmaceutical properties.
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and NO. In some embodiments, each R' is independently

alkyl or optionally substituted aryl. In other preferred

is independently selected from methyl, ethyl, propyl, isopro
pyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl,

and benzyl. In some preferred embodiments, each R" is
benzyl. In some embodiments, each R' may be indepen

independently selected from optionally substituted ethyl or

N
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R 14
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embodiments, Qis C=O. In other embodiments, each R', R,
R. R. R. R. R. and R is hydrogen. In certain embodi
ments, each RandR'' is independently selected from hydro

embodiments, each R" is -(CH2). Ar, wherein p is 1-2
embodiments, each R and R'' is hydrogen and each R" is
optionally substituted alkyl. In some embodiments, each R'

(II)
R

optionally substituted, with the proviso that R' for formula
(I) must not be hydrogen; and
each R'' is independently selected from hydrogen or

and Ar is optionally substituted phenyl. In other preferred

R8

1S

dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R,
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is

R" is independently selected from optionally substituted
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(R12)
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each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;

selected from optionally substituted alkyl, optionally substi
tuted aryl, halo, OR, NR, SR, CN, COOR, CONR, COR,
CH(OH)R, and NO. In some preferred embodiments, each

o

R6 R7

YR 7

gen, optionally Substituted alkyl, optionally Substituted aryl,
halo, OR, NR, SR, CN, COOR, CONR, COR, CH(OH)R,

N
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optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof. In some
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N
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R16 V. A

selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;
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each R, R', R'', R. R. R. R', and R' is indepen

The present invention provides piperazinylpyrimidine ana
logs which may inhibit cell proliferation and/or induce cell
apoptosis. The compounds comprise a piperazinylpyrimidine
core group that is linked to a quinazoline or a quinazoline
derivative. The quinazoline derivative may include a six
membered pyrimidine ring fused to an optionally substituted
aryl or heteroaryl ring with 5-6 ring atoms.
The compounds of the invention exert biological activity in
assays described herein. For example, compounds of the
invention are cytotoxic in a cellular screening assay described
herein. Though not limiting the invention by any theory, it is
believed that the compounds localize in the hinge region of
protein kinases and extend either through the ATP-binding
groove or towards the adjacent allosteric site. The present
invention also provides methods of preparing these com
pounds, and methods of using the same.
In one aspect, the present invention provides a compound
of formula (I), (II), or (III):
R4
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N
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wherein m is 0 or 1;
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SUMMARY
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=N

(R12)pi

dently selected from optionally substituted alkyl, optionally
substituted aryl, halo, OR, NR, SR, CN, COOR, CONR,
COR, CH(OH)R, and NO. In some preferred embodiments,

each R' is hydrogen. In the above formulas (I), (II), and (III),
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W represents a ring that includes two ring atoms of one of the
pyrimidine rings. W is typically an optionally substituted 5
or 6-membered aromatic or heteroaromatic ring that is
optionally fused to another substituted aryl, heteroaryl, het
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erocyclic, or carbocyclic group. Frequently, W is an option
ally Substituted 6-membered ring having the following struc
ture:
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wherein X and Y are N or CR':

Z is selected from the group consisting of NR", O, and S;
R’ is hydrogen or R''. In other embodiments, W may

and

include one of the following structures:

wherein each A, B, C, and D is independently NorCR' in
any combination. In certain embodiments, W may include 15
one of the following structures:
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wherein each R' is independently selected from the group

consisting of hydrogen, optionally Substituted alkyl, and
wherein each R'' is independently selected from the group 35 optionally substituted aryl. In certain embodiments, W may
consisting of hydrogen, optionally Substituted alkyl, option include one of the following structures:
ally substituted aryl, halo, OR, NR, SR, CN, COOR,
CONR, COR, CH(OH)R, and NO. In other embodiments,
W may include one of the following structures:
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W may also represent an optionally substituted 5-membered
ring having the following structure:

\ /
In some preferred embodiments, W is:
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wherein X is selected from the group consisting of NR',
Y and Z are N or CR'; and
R’ is hydrogen or R''. In certain embodiments, W is

O, and S;
65

W may also represent an optionally substituted 5-membered
ring having the following structure:

selected from the group consisting of:
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In some preferred embodiments, the compound is:
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wherein R' is selected from the group consisting of
and wherein each R" is independently selected from the

optionally substituted alkyl and optionally substituted aryl;
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group consisting of hydrogen, optionally Substituted alkyl,
optionally substituted aryl, halo, OR, NR, SR, CN, COOR,
CONR, COR, CH(OH)R, and NO. In some preferred
embodiments, the compound is:

wherein each R'' is independently selected from the group

consisting of hydrogen, optionally Substituted alkyl, and
optionally substituted aryl. In certain embodiments, W may
include one of the following structures:
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wherein R' is selected from the group consisting of
and wherein each R" is independently selected from the

optionally substituted alkyl and optionally substituted aryl;

group consisting of hydrogen, optionally Substituted alkyl,
optionally substituted aryl, halo, OR, NR, SR, CN, COOR,
CONR, COR, CH(OH)R, and NO. In some preferred
embodiments, the compound is:

50

HN \ /

wherein R' is selected from the group consisting of
optionally substituted alkyl and optionally substituted aryl;

and wherein each R" is independently selected from the

group consisting of hydrogen, optionally Substituted alkyl, 55
optionally substituted aryl, halo, OR, NR, SR, CN, COOR,
CONR, COR, CH(OH)R, and NO. In some preferred
embodiments, the compound is:
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wherein R' is selected from the group consisting of

optionally substituted alkyl and optionally substituted aryl;
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and wherein each R" is independently selected from the

group consisting of hydrogen, optionally Substituted alkyl,
optionally substituted aryl, halo, OR, NR, SR, CN, COOR,
CONR, COR, CH(OH)R, and NO. In some preferred
embodiments, the compound is:
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wherein m is 0 or 1;

In some preferred embodiments, the compound is:
35

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R7, and R is independently

selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

each R. R. R'', R. R. R. R', and R' is indepen

The present invention also provides pharmaceutical com
positions including a compound having any one of the above
formulas and at least one pharmaceutically acceptable excipi
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ent.

The present invention also provides use of a compound
having any one of the above formulas to manufacture a medi
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cament. In some embodiments, the medicament is a medica

ment for the treatment of a proliferative disorder. The present
invention also provides a method of treating a proliferative
disorder by administering a compound having any one of the

55

above formulas.

The present invention also provides a method to identify a
molecule that modulates protein kinase activity. The method
includes screening a compound having any one of the above
formulas to identify a compound having an effect on the
activity of a protein kinase.
The present invention also provides a method to treat a
proliferative disorder. The method includes administering to
a Subject in need of Such treatment, an effective amount of a
compound of formula (I), (II), or (III):

60
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dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and

each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof. In some
embodiments, the proliferative disorder is a tumor or a cancer
in a human or animal Subject. In some preferred embodi
ments, the cancer is selected from the group consisting of
leukemia, non-Small cell lung cancer, colon cancer, central
nervous system (CNS) cancer, melanoma, ovarian cancer,
renal cancer, prostate cancer, and breast cancer.
The present invention also provides a method to reduce cell
proliferation. The cells Sometimes are in a cell line. Such as a
cancer cell line (e.g., breast cancer, prostate cancer, pancre
atic cancer, lung cancer, hemopoietic cancer, colorectal can
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cer, skin cancer, ovarian cancer cell line), for example. In
Some embodiments, the cancer cell line is a leukemia, non

12
The present invention also provides a method to induce cell
death. The method includes administering to a cell in an in

Small cell lung cancer, colon cancer, central nervous system
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros

pound of formula (I), (II), or (III):

tate cancer, or breast cancer cell line. The cells sometimes are

in a tissue, can be in a Subject, at times are in a tumor, and
Sometimes are in a tumor in a subject. The method includes
administering to a cell in an in vitro or in vivo environment, an
effective amount of a compound of formula (I), (II), or (III):
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wherein m is 0 or 1;

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;
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each R. R. R'', R. R. R. R', and R' is indepen

each R'' is independently selected from hydrogen or

each R', R. R. R. R. R. R7, and R is independently
each R. R. R'', R. R. R. R', and R' is indepen

50

each R', R. R. R. R. R. R', and R is independently

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;
selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;
dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R,
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and
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dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and

each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
The above methods for reducing cell proliferation and/or
inducing cell death may also be practiced in combination with
a procedure and/or a chemotherapeutic agent. Examples of
procedures that may be used in combination with the methods
of the present invention include but are not limited to radio
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bers describing the group, though still written as e.g. C1-C6,
represent the Sum of the number of carbon atoms in the group
plus the number of such heteroatoms that are included as
replacements for carbon atoms in the ring or chain being

13
therapy or Surgery. In certain embodiments, the compounds
of the present invention are administered in combination with
one or more additional compounds, and used to reduce cell
proliferation, induce cell death, and/or ameliorate a cell pro

described.

liferative disorder.
DESCRIPTION OF DRAWING FIGURES

FIG. 1. Design strategy of compounds 3-6 and 13-24.
FIG.2. Nonlinear fit curves of the growth inhibitory (MTT
assay, 48 h treatment) effects of a sample of test compounds
against A549 (dashed curve) and MCF7 (solid curve) cell

10

lines.

FIG. 3. Dose response curves of compound 4 against four
selected PDGFR subfamily kinases obtained using the kinase
binding experiment. A non-linear least Square fit with the
Levenberg-Marquardt algorithm was implemented to fit the
curves. WHO-12 denotes for compound 4. The amount of
DNA-tagged kinase detected by qPCR (Signal; y-axis) is
plotted versus 4's concentration in nM in log 10 scale
(X-axis). Data points marked with an “X” were not used for K,

15

determination.

FIG. 4. Dose response curves of compound 4 against 7
selected PDGFR subfamily kinases obtained using the kinase
function inhibition screening. The curves were fitted using
Nonlinear regression (curve fit) implemented in the Graph
Pad Prism software (version 5.02). A Sigmoidal dose-re
sponse (variable slope) was used in this case.
FIG. 5. The overall structure-antiproliferative activity rela
tionships of piperazinylpyrimidines.
FIG. 6. The results of the MTT assay in which 4, 15, 16, and
gefitinib were screened against MDA-MB-468 cell line. (A)
Dose-response curves against MDA-MB-468 cell line. The
dose response curves plot the '% viability against the loga
rithm of the molar concentration. The error bars represent the
95% confidence interval calculated for 9n (three independent
experiments, each is a triplicate). (B) IC50 values against
MDA-MB-468 cell line (uM). The IC50 values were calcu
lated using non-linear regression analysis as described in the
experimental section.
FIG. 7. The percentage of MDA-MB-468 cells in the G2/M
stage of cell cycle upon treatment with compound 15 at dif
ferent concentrations and length of time.
FIG.8. Annexin Vassay results for MDA-MB-468 cells
treated with compound 15.
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Typically, the alkyl, alkenyl and alkynyl substituents of the
invention contain 1-10C (alkyl) or 2-10C (alkenyl oralkynyl).
Preferably they contain 1-8C (alkyl) or 2-8C (alkenyl or alky
nyl). Sometimes they contain 1-4C (alkyl) or 2-4C (alkenyl or
alkynyl). A single group can include more than one type of
multiple bond, or more than one multiple bond; Such groups
are included within the definition of the term “alkenyl' when
they contain at least one carbon-carbon double bond, and are
included within the term “alkynyl' when they contain at least
one carbon-carbon triple bond.
Alkyl, alkenyl and alkynyl groups are often substituted to
the extent that Such Substitution makes sense chemically.
Typical substituents include, but are not limited to, halo, =O.
=N CN, =N OR, =NR, OR, NR, SR, S(O)R, SOR,
SONR, NRSOR, NRCONR, NRCOOR, NRCOR, CN,
COOR, CONR, OOCR, COR, CH(OH)R, and NO, wherein
each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl,
C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl, C1-C8 acyl,
C2-C8 heteroacyl, C2-C8 alkenyl, C2-C8 heteroalkenyl,
C2-C8 alkynyl, C2-C8 heteroalkynyl, C6-C10 aryl, or
C5-C10 heteroaryl, and each R is optionally substituted with
halo, =O, —N CN, =N OR", =NR', OR, NR', SR',
SOR', SONR, NR'SOR, NRCONR, NRCOOR,
NRCOR, CN, COOR, CONR, OOCR, COR', and NO,
wherein each R" is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl,
C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or C5-C10 het
eroaryl. Alkyl, alkenyl and alkynyl groups can also be substi
tuted by C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or
C5-C10 heteroaryl, each of which can be substituted by the
Substituents that are appropriate for the particular group.
Where a substituent group contains two R or R' groups on the
same or adjacent atoms (e.g., —NR, or—NR—C(O)R), the
two R or R' groups can optionally be taken together with the
atoms in the Substituent group to which the are attached to
form a ring having 5-8 ring members, which can be substi
tuted as allowed for the R or R' itself, and can contain an
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DETAILED DESCRIPTION

additional heteroatom (N, O or S) as a ring member.
“Heteroalkyl, "heteroalkenyl', and "heteroalkynyl and
the like are defined similarly to the corresponding hydrocar
byl (alkyl, alkenyl and alkynyl) groups, but the hetero terms
refer to groups that contain 1-3O, S or N heteroatoms or
combinations thereof within the backbone residue; thus at

The following description sets forth exemplary methods,
parameters and the like. It should be recognized, however,
that such description is not intended as a limitation on the
Scope of the present proposed invention but is instead pro
vided as a description of exemplary embodiments.
1. Definitions

As used herein, the terms “alkyl.” “alkenyl and “alkynyl
include straight-chain, branched-chain and cyclic monova
lent hydrocarbyl radicals, and combinations of these, which
contain only C and H when they are unsubstituted. Examples
include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl,
2-propenyl, 3-butynyl, and the like. The total number of car
bonatoms in each Such group is sometimes described herein,
e.g., when the group can contain up to ten carbonatoms it can
be represented as 1-10C or as C1-C10 or C1-C10. When
heteroatoms (N, O and S typically) are allowed to replace
carbonatoms as in heteroalkyl groups, for example, the num
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least one carbon atom of a corresponding alkyl, alkenyl, or
alkynyl group is replaced by one of the specified heteroatoms
to form a heteroalkyl, heteroalkenyl, or heteroalkynyl group.
The typical and preferred sizes for heteroforms of alkyl, alk
enyl and alkynyl groups are generally the same as for the
corresponding hydrocarbyl groups, and the Substituents that
may be present on the heteroforms are the same as those
described above for the hydrocarbyl groups. For reasons of
chemical stability, it is also understood that, unless otherwise
specified. Such groups do not include more than two contigu
ous heteroatoms except where an oxo group is present on Nor
S as in a nitro or Sulfonyl group.
While “alkyl as used herein includes cycloalkyl and
cycloalkylalkyl groups, the term "cycloalkyl may be used
herein to describe a carbocyclic non-aromatic group that is
connected via a ring carbon atom, and “cycloalkylalkyl may
be used to describe a carbocyclic non-aromatic group that is
connected to the molecule through an alkyl linker. Similarly,
"heterocyclyl may be used to describe a non-aromatic cyclic

US 8,609.672 B2
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group that contains at least one heteroatom as a ring member
and that is connected to the molecule via a ring atom, which
may be C or N; and "heterocyclylalkyl may be used to
describe Such a group that is connected to another molecule
through a linker. The sizes and substituents that are suitable
for the cycloalkyl, cycloalkylalkyl, heterocyclyl, and hetero
cyclylalkyl groups are the same as those described above for
alkyl groups AS used herein, these terms also include rings
that contain a double bond or two, as long as the ring is not
aromatic.

As used herein, “acyl encompasses groups comprising an
alkyl, alkenyl, alkynyl, aryl or arylalkyl radical attached at
one of the two available valence positions of a carbonyl car
bonatom, and heteroacyl refers to the corresponding groups
wherein at least one carbon other than the carbonyl carbon has
been replaced by a heteroatom chosen from N, O and S. Thus
heteroacyl includes, for example, —C(=O)CR and
—C(=O)NR as well as —C(=O)-heteroaryl.
Acyl and heteroacyl groups are bonded to any group or
molecule to which they are attached through the open Valence
of the carbonyl carbon atom. Typically, they are C1-C8 acyl
groups, which include formyl, acetyl, pivaloyl, and benzoyl,
and C2-C8 heteroacyl groups, which include methoxyacetyl,
ethoxycarbonyl, and 4-pyridinoyl. The hydrocarbyl groups,
aryl groups, and heteroforms of such groups that comprise an
acyl or heteroacyl group can be substituted with the substitu
ents described herein as generally suitable substituents for
each of the corresponding component of the acyl or heteroa
cyl group.
“Aromatic' moiety or “aryl moiety refers to a monocyclic
or fused bicyclic moiety having the well-known characteris
tics of aromaticity; examples include phenyl and naphthyl.
Similarly, "heteroaromatic' and "heteroaryl' refer to such
monocyclic or fused bicyclic ring systems which contain as
ring members one or more heteroatoms selected from O. S
and N. The inclusion of a heteroatom permits aromaticity in
5-membered rings as well as 6-membered rings. Typical het
eroaromatic systems include monocyclic C5-C6 aromatic
groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl.
pyrrolyl pyrazolyl, thiazolyl, oxazolyl, and imidazolyl and
the fused bicyclic moieties formed by fusing one of these
monocyclic groups with a phenyl ring or with any of the
heteroaromatic monocyclic groups to form a C8-C10 bicyclic
group Such as indolyl, benzimidazolyl, indazolyl, benzotria
Zolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl.
pyrazolopyridyl, quinazolinyl, quinoxalinyl, cinnolinyl, and
the like. Any monocyclic or fused ring bicyclic system which
has the characteristics of aromaticity in terms of electron
distribution throughout the ring system is included in this
definition. It also includes bicyclic groups where at least the
ring which is directly attached to the remainder of the mol
ecule has the characteristics of aromaticity. Typically, the ring
systems contain 5-12 ring member atoms. Preferably the
monocyclic heteroaryls contain 5-6 ring members, and the
bicyclic heteroaryls contain 8-10 ring members.
Aryl and heteroaryl moieties may be substituted with a
variety of substituents including C1-C8 alkyl, C2-C8 alkenyl,
C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C12 aryl, C1-C8 acyl,
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group contains two R or R' groups on the same or adjacent
atoms (e.g., —NR2, or —NR—C(O)R), the two R or R'
groups can optionally be taken together with the atoms in the
Substituent group to which the are attached to form a ring
having 5-8 ring members, which can be substituted as allowed
for the Ror R' itself, and can contain an additional heteroatom
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substituted with the same substituents described above for
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and heteroforms of these, each of which can itself be further

substituted; other substituents for aryl and heteroaryl moi
eties include halo, OR, NR, SR, S(O)R, SOR, SONR,
NRSOR, NRCONR, NRCOOR, NRCOR, CN, COOR,
CONR, OOCR, COR, CH(OH)R, and NO, wherein each R
is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8
alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het
eroalkynyl, C3-C8 heterocyclyl, C4-C10 heterocyclyclalkyl,
C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or
C6-C12 heteroarylalkyl, and each R is optionally substituted
as described above for alkyl groups. Where a substituent

(N, O or S) as a ring member. The Substituent groups on an
aryl or heteroaryl group may of course be further substituted
with the groups described herein as suitable for each type of
Such substituents or for each component of the Substituent.
Thus, for example, an arylalkyl Substituent may be substi
tuted on the aryl portion with substituents described hereinas
typical for aryl groups, and it may be further Substituted on
the alkyl portion with substituents described herein as typical
or Suitable for alkyl groups.
Similarly, “arylalkyl and "heteroarylalkyl refer to aro
matic and heteroaromatic ring systems which are bonded to
their attachment point through a linking group Such as an
alkylene, including Substituted or unsubstituted, Saturated or
unsaturated, cyclic or acyclic linkers. Typically the linker is
C1-C8 alkyl or a hetero form thereof. These linkers may also
include a carbonyl group, thus making them able to provide
Substituents as an acyl or heteroacyl moiety. An aryl or het
eroaryl ring in an arylalkyl or heteroarylalkyl group may be
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aryl groups. Preferably, an arylalkyl group includes a phenyl
ring optionally substituted with the groups defined above for
aryl groups and a C1-C4 alkylene that is unsubstituted or is
substituted with one or two C1-C4 alkyl groups or heteroalkyl
groups, where the alkyl or heteroalkyl groups can optionally
cyclize to form a ring such as cyclopropane, dioxolane, or
oxacyclopentane. Similarly, a heteroarylalkyl group prefer
ably includes a C5-C6 monocyclic heteroaryl group that is
optionally substituted with the groups described above as
Substituents typical on aryl groups and a C1-C4 alkylene that
is unsubstituted or is substituted with one or two C1-C4 alkyl
groups or heteroalkyl groups, or it includes an optionally
substituted phenyl ring or C5-C6 monocyclic heteroaryland
a C1-C4 heteroalkylene that is unsubstituted or is substituted
with one or two C1-C4 alkyl or heteroalkyl groups, where the
alkyl or heteroalkyl groups can optionally cyclize to form a
ring Such as cyclopropane, dioxolane, or oxacyclopentane.
Where an arylalkyl or heteroarylalkyl group is described as
optionally substituted, the substituents may be on either the
alkyl or heteroalkyl portion or on the aryl or heteroaryl por
tion of the group. The Substituents optionally present on the
alkyl or heteroalkyl portion are the same as those described
above for alkyl groups generally; the Substituents optionally
present on the aryl or heteroaryl portion are the same as those
described above for aryl groups generally.
"Arylalkyl groups as used herein are hydrocarbyl groups
if they are unsubstituted, and are described by the total num
ber of carbonatoms in the ring and alkylene or similar linker.
Thus a benzyl group is a C7-arylalkyl group, and phenylethyl
is a C8-arylalkyl.
“Heteroarylalkyl as described above refers to a moiety
comprising an aryl group that is attached through a linking
group, and differs from “arylalkyl in that at least one ring
atom of the aryl moiety or one atom in the linking group is a
heteroatom selected from N, O and S. The heteroarylalkyl
groups are described herein according to the total number of
atoms in the ring and linker combined, and they include aryl
groups linked through a heteroalkyl linker, heteroaryl groups
linked through a hydrocarbyl linker Such as an alkylene; and
heteroaryl groups linked through a heteroalkyl linker. Thus,
for example, C7-heteroarylalkyl would include pyridylm
ethyl, phenoxy, and N-pyrrolylmethoxy.
Alkylene' as used herein refers to a divalent hydrocarbyl
group; because it is divalent, it can link two other groups
together. Typically it refers to —(CH), where n is 1-8 and
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preferably n is 1-4, though where specified, an alkylene can
also be substituted by other groups, and can be of other
lengths, and the open Valences need not be at opposite ends of
a chain. Thus —CH(Me)- and —C(Me)- may also be
referred to as alkylenes, as can a cyclic group Such as cyclo
propan-1,1-diyl. Where an alkylene group is Substituted, the
Substituents include those typically present on alkyl groups as

5

invention includes each individual isomeras well as mixtures

described herein.

In general, any alkyl, alkenyl, alkynyl, acyl, or aryl or
arylalkyl group or any heteroform of one of these groups that
is contained in a Substituent may itself optionally be substi
tuted by additional substituents. The nature of these substitu
ents is similar to those recited with regard to the primary

10

substituents themselves if the substituents are not otherwise

described. Thus, where an embodiment of, for example, R is
alkyl, this alkyl may optionally be substituted by the remain
ing substituents listed as embodiments for R' where this

15

makes chemical sense, and where this does not undermine the

size limit provided for the alkyl perse; e.g., alkyl substituted
by alkyl or by alkenyl would simply extend the upper limit of
carbon atoms for these embodiments, and is not included.

However, alkyl substituted by aryl, amino, alkoxy, —O, and
the like would be included within the scope of the invention,
and the atoms of these Substituent groups are not counted in
the number used to describe the alkyl, alkenyl, etc. group that
is being described. Where no number of substituents is speci
fied, each Such alkyl, alkenyl, alkynyl, acyl, oraryl group may
be substituted with a number of substituents according to its
available Valences; in particular, any of these groups may be
substituted with fluorine atoms at any or all of its available
Valences, for example.
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human or animal Subject. In non-limiting embodiments, the
cancer is leukemia, non-Small cell lung cancer, colon cancer,
central nervous system (CNS) cancer, melanoma, ovarian
cancer, renal cancer, prostate cancer, or breast cancer.
2. Description of the Invention

The present invention relates to piperzinylpyrimidine com
pounds having formulas (I), (II), or (III), and pharmaceuti
cally acceptable salts, esters, and prodrugs thereof. The
present invention also relates to methods for using the com
pounds described herein, Such as in screening and in treat
ment and in the preparation of a medicament or pharmaceu
tical composition for treating conditions described herein.
The compounds of the present invention may or may not
interact with hinge region and/or ATP-binding groove. Can
didate compounds were identified using anticancer cellular
assays as a first screen followed by biochemical investigation
of those compounds with encouraging cellular activity pro
files. Such an order of experiments may aid in identifying
cytotoxic or cytostatic lead compounds which may fail to
interact with their intended targets and happen to interact with
another protein family that was not anticipated. In the current
investigation, a systematic attachment of a quinazoline ring,
known as a kinase privileged fragment, to a piperazinylpyri
midine Scaffold, through linkers that positionaforementioned
fragments in different relative orientations, has been adopted
as a strategy to discover new and selective prototype kinase
The compounds of the present invention having formulas
(I), (II), or (III) are reproduced below:
(I)

R9

R

R3

4

"Sk"N / -\
X-N

N

60

R10 \

the substituents described herein as suitable for the corre

sponding group. The term also includes forms wherein Rand
R" are linked together to form a 3-8 membered ring which
may be saturated, unsaturated or aromatic and which contains
1-3 heteroatoms independently selected from N, O and S as
ring members, and which is optionally substituted with the

different tautomeric forms, and it is understood that each

tautomer is included within the scope of the invention as well.
The terms “treat,” “treatment” and “therapeutic effect” as
used herein refer to reducing or stopping a cell proliferation
rate (e.g., slowing or halting tumor growth), reducing the
number of proliferating cancer cells (e.g., removing part orall
of a tumor), or ameliorating a cell-proliferative disorder in a
human or animal Subject.
The terms “cell-proliferative disorder,” or “proliferative

inhibitors.

"Halo' as used herein includes fluoro, chloro, bromo and
iodo.

Amino” as used herein refers to NH, but where an amino
is described as “substituted” or “optionally substituted, the
term includes NR'R'" wherein each RandR" is independently
H, or is an alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl
group or a heteroform of one of these groups, and each of the
alkyl, alkenyl, alkynyl, acyl, aryl, or arylalkyl groups or het
eroforms of one of these groups is optionally substituted with

of various isomeric forms, and specifically includes racemic
mixtures as well as individual enantiomers where a single
chiral carbon is present. Where multiple chiral carbons are
present, each individual diastereomer is included as well as
mixtures that comprise a racemic mixture of one or more
diastereomer. Many of the compounds herein can exist in

disorder as used herein refers to a tumor or a cancer in a
25

“Heteroform' as used herein refers to a derivative of a

group Such as an alkyl, aryl, or acyl, wherein at least one
carbon atom of the designated carbocyclic group has been
replaced by a heteroatom selected from N, O and S. Thus the
heteroforms of alkyl, alkenyl, alkynyl, acyl, aryl, and aryla
lkyl are heteroalkyl, heteroalkenyl, heteroalkynyl, heteroa
cyl, heteroaryl, and heteroarylalkyl, respectively. It is under
stood that no more than two N, O or Satoms are ordinarily
connected sequentially, except where an oxo group is
attached to N or S to form a nitro or sulfonyl group.
"Optionally substituted as used herein indicates that the
particular group or groups being described may have no non
hydrogen Substituents, or the group or groups may have one
or more non-hydrogen Substituents. If not otherwise speci
fied, the total number of such substituents that may be present
is equal to the number of Hatoms present on the unsubstituted
form of the group being described. Where an optional sub
stituent is attached via a double bond. Such as a carbonyl
oxygen (=O), the group takes up two available Valences, so
the total number of substituents that may be included is
reduced according to the number of available valences.

18
substituents described as suitable for alkyl groups or, if
NRR" is an aromatic group, it is optionally substituted with
the Substituents described as typical for heteroaryl groups.
In many compounds within the present invention, isomers
including double bond isomers, restricted rotation isomers,
optical isomers, and mixtures of these are possible. The
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wherein m is 0 or 1;

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;
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each R', R. R. R. R. R. R', and R is independently
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The piperizinylpyrimidine compounds of the present
invention were designed to target the human kinome via
linking of a piperazinylprimidine core with a quinazoline
group either directly, as in group I, or through an orientation
linker, group II, which may offer more rigidity (n=0) or more
flexibility (n=1) (FIG. 1). Though not limiting the invention
by any theory, the designed derivatives were tailored to poten
tially localize the hinge region of kinases via their kinase
privileged fragment and extend either through the ATP-bind
ing groove or towards the adjacent allosteric site so as to be
either type-I or type-II inhibitors, respectively, or perhaps
even adopt a novel binding mode. There are two major ration
ales upon which this design strategy is based: i) because a
wide range of conformational ensembles of both active and
inactive states exist among the 518 human kinases, certain
kinases may be able to accommodate the piperazinylpyrimi
dine Scaffold attached to the quinazoline moiety; and ii)
exploiting the steric space of a given class of small molecules
with similar chemical features that are positioned differently
within the binding site may generate more than one lead
kinase inhibitor with different respective kinase selectivity
profiles and/or anticancer cellular activity.
The final compounds were mainly derived from two major
piperazinylpyrimidine key intermediates (Schemes 1 and 2:
Examples 1 and 2). Intermediate 1 was reported in the litera
ture, and the deprotection step was performed using HCl/
MeOH method (Betschart, C. et al. US 2005/0054851 A1,
2005). Intermediate 2 was synthesized using palladium cata
lyZed Suzuki cross coupling followed by deprotection as
illustrated in Scheme 2.

selected from hydrogen, optionally substituted alkyl, or
optionally substituted aryl;

each R, R', R'', R. R. R. R' and R' is indepen

dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is

optionally substituted, with the proviso that R' for formula
(I) must not be hydrogen; and
each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
The compounds of the present invention may be chiral. As
used herein, a chiral compound is a compound that is different
from its mirror image, and has an enantiomer. Furthermore,
the compounds may be racemic, or an isolated enantiomer or
Stereoisomer. Methods of synthesizing chiral compounds and
resolving a racemic mixture ofenantiomers are well knownto
those skilled in the art. See, e.g., March, Advanced Organic
Chemistry, John Wiley and Sons, Inc., New York, (1985).
Compound Synthesis
Synthetic procedures for preparing the compounds of the
present invention are illustrated in Schemes 1 and 2 and in the
Examples. Other variations in the synthetic procedures
known to those with ordinary skill in the art may also be used
to prepare the compounds of the present invention. The com
pounds are then isolated and purified by conventional meth
ods. The compounds also may be made as or converted into
salts, and in certain embodiments they are made and used as
pharmaceutically acceptable salts such as those described
herein.
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(a) K2CO3, Pd(PPh3)4, THF/H2O,
100-110° C.

(b) HCI/MeOH, rt
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Group I compounds 3-6 (see Examples 3-6) were prepared
directly by allowing the respective 4-chloroquinazoline
derivative to react with one of the piperazinylpyrimidine
intermediates (Scheme 3). Group I compounds represent the
direct attachment between the ATP-binding site localizing
quinazoline fragment and the selectivity inducing piperazi
nylpyrimidine scaffold. Intermediates 7-12 (see Examples
7-12) were synthesized by allowing m-aminobenzoic acid,
p-aminobenzoic acid; or p-aminomethylbenzoic acid to react
with the corresponding quinazoline derivative using similar
reaction conditions to those implemented in preparing group
I compounds (Scheme 4). Scheme 4 demonstrates the con
nection of the quinazoline fragment with the different linkers
implemented for group II compounds 13-24 (see Examples
13-24). Group II derivatives were prepared via coupling the
carboxylic acid group of the intermediates (7-12) with the
secondary aliphatic amine functionality of either intermedi
ate 1 or intermediate 2 using EDC/HCl and triethylamine
mixture as outlined in Scheme 5. Group II is structurally
different from group I via the incorporation of a linker
between the two major fragments. Such a linker strategy
offers three different options; m-aminophenylcarbonyl and
p-aminophenylcarbonyl provide similar rigidity level while
orienting the fragments differently whereas p-aminometh
ylphenylcarbonyl provides more flexibility that allows the
compound to cover more conformational space in orienting
the major fragments.
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3-10
7 : meta, n = 0, R = H
8 : para, n = 0, R = H
9 : para, n = 1, R = H
10 : meta, n = 0, R1 = C5H5
11: para, n = 0, R1 = C6Hs
12: para, n = 1, R1 = C6Hs
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EDC, TEA,
CHCl2

N

I( )-( )
1-2

H, R2 C6H5

5: R1 = CH5, R = CH3
6: R

=H
8: para, n = 0, R = H
9: para, n = 1, R = H
10: meta, n = 0, R1 = CH5
11: para, n = 0, R1 = CHs
12: para, n = 1, R1 = C5H5
-e-
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13-24
13: meta, n = 0, R
14: para, n = 0, R
15: para, n = 1, R
16: meta, n = 0, R
17: para, n = 0,
18:

= H, R2 = CH3 19: meta, n = 0, R1 = C6H5, R2 = CH3
= H, R = CH3 20: para, n = 0, R1 = CH5, R = CH3
=H
21: para, n = 1, R1 = CH5, R = CH3
= H, R2 = C5H5 22: meta, n = 0, R1 = C6H5, R2 = C5H5
, R = CHs 23: para, n = 0, R1 = CH5, R = CH5
s R2 C6H5 24: para, n = 1, R

C6H5, R2 C6H5

The compounds of the present invention may be designed
to be more resistant to metabolism compared by incorporat

ingahalo substituent at one or more of the R. R', R'', or R'

25

Substituents. For example, compounds 25 and 26 were Syn
thesized according to Examples 25 and 26, below. Each of
compounds 25 and 26 incorporate one—Br substituent at the

R" position and one —F substituent at one of the R' posi

30

tions.

Formulation of Compounds
As used herein, the term “pharmaceutically acceptable
salts, esters and amides' includes but are not limited to car

boxylate salts, amino acid addition salts, esters and amides of
the compounds, as well as the Zwitterionic forms thereof,

35

which are known to those skilled in the art as suitable for use

with humans and animals. (See, e.g., Berge, S. M., et al.,
“Pharmaceutical Salts.” J. Pharm. Sci. (1977) 66:1-19, which
is incorporated herein by reference.)
Any suitable formulation of the compounds described
herein can be prepared using carriers and excipients that are
well known in the art for use in a particular application. For
example, compounds may be admixed with a carrier for use in
in vitro or in vivo applications. Suitable carriers include par
tially purified water, Such as deionized water or an isotonic
Solution; buffer systems such as bicarbonate, phosphate, and
similar buffers; and mixtures of aqueous solutions with
water-miscible organic cosolvents such as acetone or DMSO.
Phosphate-buffered saline (PBS), which may be buffered to
provide a neutral pH, or in certain embodiments an acidic pH,
is sometimes preferred. Stabilizing agents may also be

40

45

50

included.

In cases where compounds are sufficiently basic or acidic
to form stable nontoxic acid or base salts, administration of

55

rate, malonate, tartarate. Succinate, benzoate, ascorbate,

60

the compounds as salts may be appropriate. Examples of
pharmaceutically acceptable salts are organic acid addition
salts formed with acids that form a physiological acceptable
anion, for example, tosylate, methanesulfonate, acetate, cit
C.-ketoglutarate, and O-glycerophosphate. Suitable inorganic
salts may also be formed, including hydrochloride, Sulfate,
nitrate, bicarbonate, and carbonate salts. Pharmaceutically
acceptable salts are obtained using standard procedures well
known in the art. For example, pharmaceutically acceptable
salts may be obtained by reacting a sufficiently basic com
pound Such as an amine with a suitable acid affording a

65
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physiologically acceptable anion. Alkali metal (e.g., Sodium,
potassium or lithium) or alkaline earth metal (e.g., calcium,
magnesium) salts of carboxylic acids and other anionic
groups in molecules within the invention also are contem
plated.
A compound may be formulated as a pharmaceutical com
position and administered to a mammalian host in need of
Such treatment. Forpharmaceutical applications, a compound
is typically combined with a pharmaceutically acceptable
carrier Such as water or other pharmaceutically acceptable
excipients. In one embodiment, the mammalian host is
human. Any Suitable route of administration may be used,
including but not limited to oral, parenteral, intravenous,
intramuscular, topical and Subcutaneous routes.
In one embodiment, a compound is administered systemi
cally (e.g., orally) in combination with a pharmaceutically
acceptable vehicle Such as an inert diluent or an assimilable
edible carrier. They may be enclosed in hard or soft shell
gelatin capsules, compressed into tablets, or incorporated
directly with the food of the patients diet. For oral therapeu
tic administration, the active compound may be combined
with one or more excipients and used in the form of ingestible
tablets, buccal tablets, troches, capsules, elixirs, Suspensions,
syrups, wafers, and the like. Such compositions and prepara
tions should contain at least 0.1% of active compound. The
percentage of the compositions and preparations may be var
ied and may conveniently be between about 2 to about 60% of
the weight of a given unit dosage form. The amount of active
compound in Such therapeutically useful compositions is
such that an effective dosage level will be obtained.
Tablets, troches, pills, capsules, and the like also may con
tain the following: binders such as gum tragacanth, acacia,
corn starch or gelatin; excipients such as dicalcium phos
phate; a disintegrating agent such as corn starch, potato
starch, alginic acid and the like; a lubricant Such as magne
sium Stearate; and a Sweetening agent such as Sucrose, fruc
tose, lactose or aspartame or a flavoring agent such as pep
permint, oil of wintergreen, orcherry flavoring may be added.
When the unit dosage form is a capsule, it may contain, in
addition to materials of the above type, a liquid carrier, Such
as a vegetable oil or a polyethylene glycol. Various other
materials may be present as coatings or to otherwise modify
the physical form of the Solid unit dosage form. For instance,
tablets, pills, or capsules may be coated with gelatin, wax,
shellac or Sugar and the like. A syrup or elixir may contain the
active compound. Sucrose or fructose as a Sweetening agent,
methyl and propylparabens as preservatives, a dye and fla
Voring Such as cherry or orange flavor. Any material used in
preparing any unit dosage form is pharmaceutically accept
able and Substantially non-toxic in the amounts employed. In
addition, the active compound may be incorporated into Sus
tained-release preparations and devices.
The active compound also may be administered intrave
nously or intraperitoneally by infusion or injection. Solutions
of the active compound or its salts may be prepared in a
buffered solution, optionally mixed with a nontoxic surfac
tant. Dispersions can also be prepared in glycerol, liquid
polyethylene glycols, triacetin, and mixtures thereof and in
oils. Under ordinary conditions of storage and use, these
preparations contain a preservative to prevent the growth of
microorganisms
The pharmaceutical dosage forms suitable for injection or
infusion can include sterile aqueous solutions or dispersions
or sterile powders comprising the active ingredient that are
adapted for the extemporaneous preparation of sterile inject
able or infusible solutions or dispersions, optionally encap
Sulated in liposomes. In all cases, the ultimate dosage form
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carrier(s) and/or excipient(s) in liquid form or finely divided
Solid form, or both, and then shaping the product if required.

should be sterile, fluid and stable under the conditions of

manufacture and storage. The liquid carrier or vehicle can be
a solvent or liquid dispersion medium comprising, for
example, water, ethanol, a polyol (for example, glycerol,
propylene glycol, liquid polyethylene glycols, and the like),
Vegetable oils, nontoxic glyceryl esters, and Suitable mixtures
thereof. The proper fluidity can be maintained, for example,
by the formation of liposomes, by the maintenance of the
particle size in the case of dispersions or by the use of Surfac
tants. The prevention of the action of microorganisms can be
brought about by various antibacterial and antifungal agents,
for example, parabens, chlorobutanol, phenol, Sorbic acid,
thimerosal, and the like. In many cases, it will be preferable to
include isotonic agents, for example, Sugars, buffers or
sodium chloride. Prolonged absorption of the injectable com
positions can be brought about by the use in the compositions
of agents delaying absorption, for example, aluminum
monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating
the active compound in the required amount in the appropri
ate solvent with various of the other ingredients enumerated
above, as required, followed by filter sterilization. In the case
of sterile powders for the preparation of sterile injectable
Solutions, the preferred methods of preparation are vacuum
drying and the freeze drying techniques, which yield a pow
der of the active ingredient plus any additional desired ingre
dient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be
applied in liquid form. Compounds often are administered as
compositions or formulations, in combination with a derma
tologically acceptable carrier, which may be a solid or a
liquid. Examples of useful dermatological compositions used
to deliver compounds to the skin are known (see, e.g., Jac
quet, et al. (U.S. Pat. No. 4,608.392), Geria (U.S. Pat. No.
4,992.478), Smith, et al. (U.S. Pat. No. 4,559,157) and Wortz
man (U.S. Pat. No. 4,820,508).
Compounds may be formulated with a solid carrier, which
include finely divided Solids such as talc, clay, microcrystal
line cellulose, silica, alumina and the like. Useful liquid car
riers include water, alcohols or glycols or water-alcohol/gly
col blends, in which the present compounds can be dissolved
or dispersed at effective levels, optionally with the aid of
non-toxic Surfactants. Adjuvants such as fragrances and addi
tional antimicrobial agents can be added to optimize the prop
erties for a given use. The resultant liquid compositions can
be applied from absorbent pads, used to impregnate bandages
and other dressings, or sprayed onto the affected area using
pump-type or aerosol sprayers. Thickeners such as synthetic
polymers, fatty acids, fatty acid salts and esters, fatty alco

Methods

The present invention provides a method to identify a mol
ecule that modulates protein kinase activity. The method
includes screening a compound described herein, to identify
a compound having an effect on the activity of a protein
kinase.
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wherein m is 0 or 1;

50

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R7, and R is independently

55

selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

each R, R', R'', R. R. R. R', and R' is indepen

sometimes from about 0.5 wt % to about 10 wt %. The

concentration in a semi-solid or solid composition Such as a
gel or a powder often is about 0.1 wt % to about 5 wt %,
sometimes about 0.5 wt % to about 2.5 wt %. Higher concen
trations are also appropriate for Some solid or semi-solid
compositions, and may include amounts up to about 25 wt %
or up to about 50 wt % or more. A compound composition
may be prepared as a unit dosage form, which is prepared
according to conventional techniques known in the pharma
ceutical industry. In general terms, such techniques include
bringing a compound into association with pharmaceutical

(I)
R!

hols, modified celluloses or modified mineral materials can

also be employed with liquid carriers to form spreadable
pastes, gels, ointments, soaps, and the like, for application
directly to the skin of the user.
Generally, the concentration of the compound in a liquid
composition often is from about 0.1 wt % to about 25 wt %,

The present invention also provides a method to treat a
proliferative disorder. The method includes administering to
a Subject in need of Such treatment, an effective amount of a
compound of formula (I), (II), or (III):

60
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dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and
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each Q is CH, SO, or C=O;

each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
The present invention also provides a method to treat a
proliferative disorder. In some embodiments, the proliferative
disorder is a tumor or a cancer in a human or animal Subject.
In Some preferred embodiments, the cancer may be leukemia,
lung cancer, non-Small cell lung cancer, hemopoietic cancer,

each R', R. R. R. R. R. R7, and R is independently
selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

each R. R. R'', R. R. R. R', and R' is indepen

colorectal cancer, colon cancer, skin cancer, central nervous

system (CNS) cancer, melanoma, ovarian cancer, renal can
cer, prostate cancer, ovarian cancer, or breast cancer. In some
preferred embodiments, the cancer may be leukemia, non
Small cell lung cancer, colon cancer, central nervous system
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros

10

tate cancer, or breast cancer.

15

The present invention also provides a method to reduce cell
proliferation. The cells Sometimes are in a cell line. Such as a
cancer cell line (e.g., breast cancer, prostate cancer, pancre
atic cancer, lung cancer, hemopoietic cancer, colorectal can
cer, skin cancer, ovarian cancer cell line), for example. In

dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR; S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and

each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
A compound having any one of the above formulas may

Some embodiments, the cancer cell line is a leukemia, non

also be used in methods to induce cell death. The method

Small cell lung cancer, colon cancer, central nervous system
(CNS) cancer, melanoma, ovarian cancer, renal cancer, pros

includes administering to a cell in an in vitro or in vivo
environment, an effective amount of a compound of formula
(I), (II), or (III):

tate cancer, or breast cancer cell line. The cells sometimes are

in a tissue, can be in a Subject, at times are in a tumor, and
Sometimes are in a tumor in a subject. The method includes
administering to a cell in an in vitro or in vivo environment, an
effective amount of a compound of formula (I), (II), or (III):
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wherein m is 0 or 1;

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;

R 14

Sos

R

55

N

R 15

R

R 16

R 14

N

R 14RN,N 1N2

N-Q

(R12)pi

R

=N

R5

R

(III)
R

=x "k
N

N

7

iii.
R

R9

R. R.
R

R

R10 N X-N

21

)

R

40

1n

45

8

R6 R7 R

(R12)

R9

R n7

Sk

N

R8

R6 R7

R8

R. R.
R

R10 \ X-N

R5

N

35

(II)
R

R.

R11

(R12)

R9

R10 \

(I)

R3

65

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with or
bonded to one or more additional aryl, heterocyclic, or het
eroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R', and R is independently

selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;
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lated from 9% area under the peak (AEP). All final purified
compounds showed purity levels greater than 95%.
Example 1

each R, R', R'', R', R', R', R', and R' is indepen

dently selected from hydrogen, optionally Substituted alkyl,
or optionally substituted aryl, halo, OR, NR, SR, S(O)R.
SOR, SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and NO,
wherein each R is independently H, C1-C8 alkyl, C2-C8
heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8
alkynyl, C2-C8 heteroalkynyl, C3-C8 heterocyclyl, C4-C10
heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12
arylalkyl, or C6-C12 heteroarylalkyl, and wherein each R is
optionally substituted; and

Preparation of 5-ethyl-2-(piperazin
1-yl)pyrimidine (1)
10

each R'' is independently selected from hydrogen or

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
The compounds of the present invention may be used for
research purposes, as the compounds show overall selectivity
towards certain kinase Subfamilies. The compounds may be
used to identify the efficacy of modulating kinase activity of

15

mp: 67-68° C. "H-NMR (DMSO-d6): 8 1.19 (t, J–7.56 Hz,
4H), 3.76 (t, J=4.8 Hz, 4H), 8.19 (s. 2H). 'C-NMR (DMSO

3H), 1.46 (s.9H), 2.47 (q, J=7.56 Hz, 2H), 3.49 (t, J=4.8 Hz,

certain combinations of kinase subfamilies in cells. The

present invention also provides a composition comprising an
isolated protein kinase complexed with a compound of for
mula (I), (II), or (III). Such complexes are useful for the
information they provide about the binding site of a modu
lating compound to the particular kinase, and as a research
tool for analyzing the structure of the kinase. Such complexes
are also useful because they may be more readily crystallized
than the uncomplexed kinase, allowing crystallization and
crystal structure determination where it would not be possible
without the bound modulating compound.

25

temperature. Methanol was removed using a row: evaporator.
The residue was dissolved in water; the solution was neutral
30

The following examples are offered to illustrate but not to
General Chemistry
All temperatures are expressed in C. (degrees centigrade).
All reagents, solvents, and starting materials were obtained
from commercial suppliers and used without further purifi
cation. Reactions requiring anhydrous conditions were per
formed in dry solvents under Argon atmosphere. Reactions
were monitored by thin layer chromatography (TLC) on pre
coated silica gel F254 plates (EMD) using a UV detector for
visualization. Flash column chromatography was performed

with EMD 230-400 mesh silica gel 60 A. Yields are of puri
fied products. Melting points were determined using Thomas
Hoover melting point apparatus and are uncorrected. "H
NMR and 'C NMR spectra were recorded on a Jeol JNM

ECA600 spectrometer. The obtained FID of each experiment
was processed using Delta NMRID processor software. The
chemical shifts are expressed in parts per million (ppm) down
field from TMS. Spin multiplicities are designated as s (sin
glet), d (doublet), dd (doublet of doublets), ddd (doublet of
doublet of doublets), t (triplet), q (quartet), m (multiplet), and
br (broad). Mass spectra (MS) were determined by MALDI
instrument. 1 uL test compound solution in acetonitrile is
mixed with an equal amount of the matrix Solution (saturated
2,5-dihydroxybenzoic acid in 50% ethanol) on the MALDI
plate. MALDI spectra were recorded in positive reflectron
mode on an AXIMA curved-field reflectron (CFR) MALDI
TOF mass spectrometer using a quadrupole ion-trap (QIT)
MALDI-TOF instrument (Kratos/Shimadzu, Columbia, Md.,
USA). Analytical HPLC was performed using a C18 Phe
nomenex quantitative 5 um 4.6 mmx 150 mm column with a
30 minute gradient of solvent from 10% to 90% CHCN in
HO. Retention time (R) was recorded in minutes and purity
was indicated as percentage of the target compound calcu

d6): 8 15.59, 22.66, 28.4, 43.76, 43.77, 79.8, 124.95, 154.84,
157.08, 160.05. MS: calcd 292.19 for CHNO, MI".
found, 293.19 M+1". b) HC1/MeOH mixture was prepared
by adding 10 ml acetylchloride dropwise to 100 ml methanol
at 0°C. The resulting mixture was warmed to room tempera
ture. The intermediate from step a (9 gm, 30.8 mmol) was
then added to the HC/MeOH and stirred for 12 h at room

EXAMPLES
limit the invention.

a) A mixture of tert-butyl piperazine-1-carboxylate (6.5
gm, 35.2 mmol), 2-chloro-4-ethylpyrimidine (5 gm, 35.2
mmol), triethylamine (3.55 gm, 35.2 mmol), and absolute
ethanol (60 ml) were refluxed for 12 h and then cooled. Ice
water was added and the resulting precipitate was filtered,
washed with cold water, and finally dried to afford the desired
crude intermediate, tert-butyl 4-(5-ethylpyrimidin-2-yl)pip
erazine-1-carboxylate, as white flakes (9.24 gm, 90% yield);

ized using solid NaHCO. The mixture was extracted with
CHCl (3x200 mL). The combined organic layers was
washed successively with saturated NaHCO, and saturated
brine and then dried with anhydrous NaSO. Concentration
of the organic layer afforded the desired crude product 1 as a

white solid (4.8 gm, 81% yield); mp: 115-116° C. "H-NMR
35

(DMSO-d6): 8 1.20 (t, J=7.56 Hz, 3H), 2.48 (q, J=7.56 Hz,
2H), 3.09 (t, J=5.16 Hz, 4H), 3.94 (t, J=5.16 Hz, 4H), 8.19 (s.

2H). 'C-NMR (DMSO-d6): & 15.53, 22.67, 42.76, 44.30,
125.52, 157.15, 160.09.

40

Example 2
Preparation of 5-benzyl-2-(piperazin
1-yl)pyrimidine (2)

45

50

55

60

a) A mixture of KCO (6 gm, 43.5 mmol. 3 equiv) and
Pd(PPh) (1 gm, 0.86 mmol) were stirred at room tempera
ture in 20 mL THF/water (1:1) for 30 minutes. Tert-butyl
4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (5 gm,
14.5 mmol. 1 equiv) was then added with B-benzyl-9-BBN (2
equiv. 49 ml of a 0.5 M solution in THF). The resulting
mixture was heated with stirring under argon atmosphere in
an oil bath adjusted at 100-110° C. until the reaction had
reached completion, as monitored by TLC. The reaction mix
ture was extracted with CHCl (3x200 mL). The combined
organic layers were then dried with anhydrous NaSO. Chlo
roform was evaporated under reduced pressure and the resi
due was purified using flash column chromatography (ini
tially with 4:1 hexane/ethyl acetate and finally with 1:1
hexane/ethyl acetate). Tert-butyl 4-(5-benzylpyrimidin-2-yl)
piperazine-1-carboxylate was obtained as a yellow solid (3.8

gm, 74% yield); mp: 121-123° C. "H-NMR (DMSO-d6): 8
1.47 (s.9H), 3.47 (t, J–4.68 Hz, 4H), 3.75 (t, J=4.68 Hz, 4H),
3.78 (s. 2H), 7.14-7.29 (m, 5H), 8.16 (s. 2H). 'C-NMR
(DMSO-d6): 8 28.4, 35.61, 43.70, 79.92, 122.29, 126.41,

65

128.51, 128.66, 140.02, 154.84, 157.87, 160.69. MS: calcd

354.21 for C20HNO, MI. found, 355.21 M+1. b)3.7
gm of the obtained product from step a was then deprotected

US 8,609.672 B2
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using HCl/MeOH as described above in the preparation of 1.
As a result, compound 2 was obtained as a pale yellow solid

32
157.13, 158.08, 160.36, 164.12. MS: calcd 396.21 for

CHN MI". found, 397.4 M+1".
Example 6

(2.2gm, 80% yield); mp: 108-110° C. "H-NMR (DMSO-d6):
& 1.89 (s, 1H), 2.93 (t, J–4.8 Hz, 4H), 3.76 (t, J–4.8 Hz, 4H),

3.79 (s. 2H), 7.17-729 (m, 5H), 8.18 (s. 2H). 'C-NMR
(DMSO-d6): 8 35.59, 44.96, 45.92, 121.79, 126.34, 128.48,
128.6, 140.1, 157.8, 160.5. MS: calcd 254.15 for C15HN
M. found, 255.15 M+1.
Example 3

Preparation of 4-(4-(5-benzylpyrimidin-2-yl)piper
azin-1-yl)-2-phenylduinazoline (6)
10

Preparation of 4-(4-(5-ethylpyrimidin-2-yl)piper
azin-1-yl)guinazoline (3)
A mixture of 1 (72 mg, 0.377 mmol), 4-chloroquinzoline
(61 mg, 0.377 mmol), and triethylamine (38 mg, 0.377 mmol)
in isopropanol (5 ml) was refluxed at 80°C. for 1.5 hr. The
solid separated out of the reaction was filtered, washed with
hot solvent and dried to afford compound 3 which was
obtained as a yellow solid (61 mg, 50% yield); mp: >250° C.
The purity of 3 was confirmed using HPLC (97.27%,

15

125.4, 126.11, 127.95, 128.35, 128.56, 130.32, 132.89,
138.02, 140.9, 152.11, 157.81, 158.06, 160.26, 164.09. MS:

calcd 458.22 for CHN MI". found, 458.28 MI".
Examples 7-12
25

General Preparation of
quinazoline-4-ylaminobenzoic acid and
quinazoline-4ylaminomethylbenzoic acid
intermediates (7-12)

113.28, 121.66, 125.04, 126.69, 126.88, 134.78, 143.5,
149.89, 157.19, 159.95, 162.51. MS: calcd 320.17 for

Preparation of 4-(4-(5-benzylpyrimidin-2-yl)piper
azin-1-yl)guinazoline (4)
Compound 4 was prepared from 2 (90 mg, 0.354 mmol)
and 4-chloroquinzoline (58 mg, 0.354 mmol) following the
general procedure for the preparation of 4. The product was a
yellow solid (86 mg, 63%); mp: >250°C. The purity of 4 was

30

35

sumed. The solid furnished out of the reaction, after solvent
40

cation or elucidation.

Example 13

(DMSO-d6): 83.8 (s. 2H), 3.96 (t, J=5.16 Hz, 4H), 4.26 (t,
J=5.16 Hz, 4H), 7.17-7.3 (m, 5H), 7.71 (ddd, J=2.22 Hz,
J=6.36 Hz, J=8.4 Hz, 1H), 8.01 (m, 2H), 8.25 (d. J=8.4 Hz,

45

34.51, 42.6, 48.69, 112.49, 119.73, 123.03, 126.11, 126.98,
127.32, 128.32, 128.54, 135.36, 140.86, 140.96, 148.74,

157.84, 159.77, 162.12. MS: calcd 382.19 for CHN
M", found, 383.35 M+1".
Example 5

Either 4-chloroquinzoline or 2-phenyl-4-chloroquinzoline
was reacted with an equivalent amount of the corresponding
aminobenzoic acid or aminomethylbenzoic acid derivative in
the presence of an equivalent amount of triethylamine using
anhydrous isopropanol as a solvent. The reaction was per
formed under 80° C. until the starting materials were con
evaporation, was washed with hot water to remove triethy
lamine HCl and used in the next step without further purifi

confirmed using HPLC (97.59%, R=15.025). H-NMR
1H), 8.34 (s. 2H), 8.86 (s, 1H). 'C-NMR (DMSO-d6): 8

(m, 8H), 7.17-7.30 (m, 5H), 7.49-7.54 (m, 4H), 7.82 (ddd,
J=0.78 Hz, J=6.6 Hz, J–7.92 Hz, 1H), 7.9 (d. J=8.28 Hz, 1H),
(DMSO-d6): 8 34.56, 43.24, 48.81, 114.74, 122.82, 125.35,

(s, 1H). 'C-NMR (DMSO-d6): & 15.63, 21.91, 42.85, 48.78,

C18HN MI". found, 320.39 (MI".
Example 4

R=19.707). 'H-NMR (DMSO-d6): 83.79 (s. 2H), 3.91-3.96
8.08 (d. J=8.28 Hz, 1H), 8.32 (s.2H), 8.51 (m,2H). 'C-NMR

R=9.987). 'H-NMR (DMSO-d6): 8 1.13 (t, J–7.56 Hz, 3H),
2.45 (q, J=7.56 Hz, 2H), 3.95 (t, J=5.28 Hz, 4H), 4.16 (t,
J=5.28 Hz, 4H), 7.68 (ddd, J=1.38 Hz, J=6.84 Hz, J=8.4 Hz,
1H), 7.96 (m, 2H), 8.22 (d. J=8.4 Hz, 1H), 8.31 (s. 2H), 8.82

Compound 6 was prepared from 2 (90 mg, 0.354 mmol)
and 2-phenyl-4-chloroquinzoline (84 mg. 0.354 mmol) fol
lowing the general procedure for the preparation of 3. The
product was a white solid (160 mg. 98%); mp: 135-137° C.
The purity of 6 was confirmed using HPLC (98.57%,

50

Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin
1-yl)(3-(quinazolin-4-ylamino)phenyl)methanone
(13)
Intermediate 1 (72 mg, 0.377 mmol) was reacted with
intermediate 7 (99 mg 0.377 mmol) in the presence of
equivalent amounts of both EDC.HCl (72 mg 0.377 mmol)
and TEA (38 mg 0.377 mmol) using 5 ml of CH2Cl as a
solvent. The reaction mixture was stirred under room tem

Preparation of 4-(4-(5-ethylpyrimidin-2-yl)piper
azin-1-yl)-2-phenylduinazoline (5)
55

Compound 5 was prepared from 1 (72 mg, 0.377 mmol)
and 2-phenyl-4-chloroquinzoline (90 mg. 0.377 mmol) fol
lowing the general procedure for the preparation of 3. The
product was a white solid (100 mg, 67%); mp: 137-138°C.
The purity of 5 was confirmed using HPLC (96.43%,

'H-NMR (DMSO-d6): 8 1.12 (t, J=7.44 Hz, 3H), 2.43 (q.

60

R=1509). 'H-NMR (DMSO-d6): 8 1.14 (t, J–7.56 Hz, 3H),

2.44 (q, J=7.56 Hz, 2H), 3.93-3.98 (m, 8H), 7.50-7.54 (m,
4H), 7.83 (ddd, J=1.38 Hz, J=6.84 Hz, J=8.28 Hz, 1H), 7.9
(dd, J=0.96 Hz, J=8.28 Hz, 1H), 8.1 (dd, J=0.96 Hz, J=8.28

HZ, 1H), 8.3 (s. 2H), 8.51 (m, 2H). 'C-NMR (DMSO-d6): 8
15.6, 21.93, 43.33, 48.85, 114.75, 119.3, 123.55, 125.36,
125.4, 127.96, 128.37, 130.31, 132.9, 138.03, 152.11,

perature overnight. The solvent was evaporated under pres
Sure and the title compound was purified using flash column
chromatography (2.5% MeOH in CHCl). The product was
a white solid (107 mg, 64%); mp: 146-147°C. The purity of
13 was confirmed using HPLC (97.1%, R=11.075).

65

J=7.44 Hz, 2H), 3.35-3.79 (br, m, 8H), 7.2 (dd, J=1.2 Hz,
J=7.74 Hz, 1H), 7.48 (t, J=7.92 Hz, 1H), 7.65 (ddd, J=1.38
Hz, J=7.38 Hz, J=8.28 Hz, 1H), 7.8 (dd, J=1.2 Hz, J=7.38 Hz,
1H), 7.87 (ddd, J=1.38 Hz, J=7.08 Hz, J=8.28 Hz, 1H), 7.98
(ddd, J=0.72 Hz, J=1.8 Hz, J=8.28 Hz, 1H), 8.02 (t, J=1.68
HZ, 1H), 8.27 (s. 2H), 8.57 (dd, J=0.72 Hz, J=7.74 Hz, 1H),

8.63 (s, 1H), 9.93 (s, 1H). 'C-NMR (DMSO-d6): & 15.58,

21.9, 41.49, 43.34, 43.87, 46.95, 115.16, 120.82, 122.17,
122.97, 123.18, 125.01, 126.38, 127.85, 128.67, 133.13,

US 8,609.672 B2
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135.88, 139.23, 149.7, 154.36, 157.13, 157.67, 16024,

'C-NMR (DMSO-d6): 8 34.53, 41.5, 43.25, 43.78, 46.9,

169.02. MS: calcd 439.21 for CHNO IMI". found,

115.15, 120.82, 122.17, 122.96, 123.18, 126.12, 126.38,
127.86, 128.34, 128.56, 128.67, 133.13, 139.23, 140.87,
149.7, 154.36, 157.67, 157.81, 160.17, 169.02. MS: calcd

439.12 Mt.

Example 14
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin
1-yl)(4-(quinazolin-4-ylamino)phenyl)methanone
(14)
Compound 14 was prepared from intermediate 1 (72 mg,
0.377 mmol) and intermediate 8 (99 mg, 0.377 mmol) fol
lowing the same procedure utilized in the preparation of 13.
The product obtained was a white solid (100 mg, 60%); mp:
248-249° C. The purity of 14 was confirmed using HPLC

501.23 for C30H.N.O.M. found, 501.95 |M|.
Example 17
10

Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(4-(quinazolin-4-ylamino)phenyl)methanone
(17)

15

Compound 17 was prepared from intermediate 2 (90 mg.
0.354 mmol) and intermediate 8 (93 mg 0.354 mmol) fol
lowing the procedure used in the preparation of compound
13. The product obtained was a white solid (135 mg, 76%);
mp: 245-247°C. The purity of 17 was confirmed using HPLC

(95%, R=10.753). "H-NMR (DMSO-d6): & 1.12 (t, J=7.56

Hz, 3H), 2.43 (q, J–7.56 Hz, 2H), 3.33-3.84 (br, m, 8H), 7.5
(d. J=8.64 Hz, 2H), 7.66 (ddd, J=1.38, HZ, J–7.2 Hz, J=8.28
HZ, 1H), 7.82 (d. J=8.28 Hz, 1H), 7.88 (ddd, J=1.38 Hz, J=7.2
HZ, J=8.28 Hz, 1H), 8.02 (d. J–8.64 Hz, 2H), 8.27 (s. 2H),

(96.73%, R=14.952). 'H-NMR (DMSO-d6): 83.05-3.8 (br.

m, 10H), 7.18-7.31 (m, 5H), 7.5 (d. J=8.64 Hz, 2H), 7.67
(ddd, J=1.38, HZ, J–7.2 Hz, J=8.1 Hz, 1H), 7.82 (d. J=8.28
HZ, 1H), 7.89 (ddd, J=1.2 Hz, J=6.96 Hz, J=8.28 Hz, 1H),
8.04 (d. J=8.64 Hz, 2H), 8.32 (s. 2H), 8.65 (d. J=8.1 Hz, 1H),

8.59 (d. J=8.46 Hz, 1H), 8.66 (s, 1H), 9.93 (s, 1H). 'C-NMR
(DMSO-d6): 8 15.53, 21.87, 41.55, 43.6, 46.95, 115.19,

8.67 (s, 1H), 10.01 (s, 1H). 'C-NMR (DMSO-d6): 8 34.50,

121.34, 122.99, 124.92, 126.37, 127.62, 127.78, 127.84,
130.37, 133.12, 140.57, 149.72, 1542, 157.1, 157.55, 1602,

169.08. MS: calcd 439.21 for C.H.N.O MI". found,
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439.16 Mt.

169.09. MS: calcd 501.23 for C30H NO IMI". found,

Example 15
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin
1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl)
methanone (15)
Compound 15 was prepared from intermediate 1 (77 mg,
0.405 mmol) and intermediate 9 (113 mg, 0.405 mmol) fol
lowing the general procedure used in the preparation of 13.
The product obtained was a white solid (40 mg, 21%); mp:
170-171° C. The purity of 15 was confirmed using HPLC

501.74 M.
30

J=7.56 Hz, 1H), 8.46 (s, 1H), 8.9 (t, J=5.82 Hz, 1H). C

35
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m, 10H), 4.89 (d. J=5.82 Hz, 2H), 7.22-7.34 (m, 5H), 7.43 (d.
J=8.28 Hz, 2H), 7.49 (d. J=8.28 Hz, 2H), 7.6 (ddd, J=1.2 Hz,
J=6.72 Hz, J=8.28 Hz, 1H), 7.76 (dd, J=0.84 Hz, J-7.56 Hz,
1H), 7.84 (ddd, J=1.2 Hz, J=6.72 Hz, J=8.28 Hz, 1H), 8.34 (s,
2H), 8.36 (d. J=7.92 Hz, 1H), 8.51 (s, 1H), 8.94 (t, J=5.82 Hz,

1H). 'C-NMR (DMSO-d6): 8 34.49, 43.23, 114.86, 122.61,

114.88, 122.63, 124.97, 125.77, 127.09, 127.23, 127.57,
132.67, 134.27, 141.11, 149.17, 155.05, 157.12, 159.37,

160.18, 169.13. MS: calcd 453.23 for C.H.N.O MI".
50

122.89, 125.74, 126.09, 127.07, 127.2, 127.54, 128.31,
128.53, 132.62, 134.23, 140.83, 141.09, 149.17, 155.02,
157.77, 159.36, 160.1, 169.1. MS: calcd 515.24 for

C31H NO IMI". found, 515 MI".
Example 19

Example 16
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(3-(quinazolin-4-ylamino)phenyl)methanone
(16)

55

Compound 16 was prepared from intermediate 2 (90 mg.
0.354 mmol) and intermediate 7 (93 mg 0.354 mmol) fol
lowing the same procedure utilized in the preparation of 13.
The product obtained was a white solid (125 mg, 70%); mp:
120-122°C. The purity of 16 was confirmed using HPLC

60

(97.17%, R=15.488). 'H-NMR (DMSO-d6): 83.34-3.78 (br.

m, 10H), 7.17-729 (m, 6H), 7.48 (t, J=7.92 Hz, 1H), 7.65
(ddd, J=0.96 Hz, J=6.96 Hz, J=8.88 Hz, 1H), 7.8 (d. J=7.56
HZ, 1H), 7.87 (im. 1H), 7.98 (m. 1H), 8.02 (s, 1H), 8.31 (s,
2H), 8.56 (d. J=7.92 Hz, 1H), 8.62 (s, 1H), 9.92 (s, 1H).

Compound 18 was prepared from intermediate 2 (102 mg,
0.405 mmol) and intermediate 9 (113 mg, 0.405 mmol) fol
lowing the general procedure used in the preparation of 13.
The product obtained was a white solid (40 mg, 19%); mp:
99-101° C. The purity of 18 was confirmed using HPLC

(96.14%, R=15.95). "H-NMR (DMSO-d6): 83.37-3.83 (br.

NMR (DMSO-d6): 8 15.58, 21.89, 43.25, 43.75, 46.92,
found, 453 M".

Example 18

Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(4-((quinazolin-4-ylamino)methyl)phenyl)
methanone (18)

(95.48%, R=11.288). 'H-NMR (DMSO-d6): 8 1.11 (t,

J–7.56 Hz, 3H), 2.42 (q, J=7.56 Hz, 2H), 3.34-3.76 (br, m,
8H), 4.84 (d. J=5.82 Hz, 2H), 7.4 (d. J=8.4 Hz, 2H), 7.44 (d.
J=8.4 Hz, 2H), 7.54 (ddd, J=1.2 Hz, J=6.72 Hz, J=8.28 Hz,
1H), 7.7 (dd, J=0.84 Hz, J-7.56 Hz, 1H), 7.78 (ddd, J=1.2 Hz,
J=6.72 Hz, J–8.28 Hz, 1H), 8.26 (s. 2H), 8.31 (dd, J=0.84 Hz,

43.52, 45.38, 115.20, 121.73, 122.87, 123.11, 126.08,
126.35, 127.75, 127.8, 128.3, 128.51, 130.34, 133.12,
140.59, 140.83, 149.69, 154.27, 157.57, 157.78, 160.13,

Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin
1-yl)(2-(3-phenylduinazolin-4-ylamino)phenyl)
methanone (19)
Compound 19 was prepared from intermediate 1 (120 mg.
0.625 mmol) and intermediate 10 (213 mg 0.625 mmol)
following the same procedure utilized in the preparation of
13. The product obtained was a white solid (210 mg, 40%);
mp: 204-205°C. The purity of 19 was confirmed using HPLC

(97.67%, R=15.123). "H-NMR (DMSO-d6): 8 1.09 (t, 3H),
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2.4 (q, 2H), 3.16-3.71 (m, 8H), 7.18 (d. J–7.56 Hz, 1H),
7.41-7.59 (m, 5H), 7.83 (m, 2H), 8.02 (m, 1H), 8.13 (m, 1H),
8.21 (s. 2H), 8.4 (m, 2H), 8.54 (d. J=8.22 Hz, 1H), 9.87 (s,

US 8,609.672 B2
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1H). 'C-NMR (DMSO-d6): 8 15.36, 21.85, 42.66, 44.25,

140.85, 150.49, 157.77, 157.85, 158.92, 160.15, 169.14. MS:

calcd 577.26 for C36H, NOMI". found, 577.55 Mt.
Example 23
calcd 515.24 for C31HNOMI". found, 515.84 |M|..
5
Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(4-(2-phenylquinazolin-4ylamino)phenyl)
Example 20
methanone (23)
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin
Compound 23 was prepared from intermediate 2 (120 mg.
10
1-yl)(2-(4-phenylquinazolin-4-ylamino)phenyl)
0.472 mmol) and intermediate 11 (160 mg. 0.472 mmol)
following the same procedure utilized in the preparation of
methanone (20)
13. The productobtained was a white solid (70 mg, 12%); mp:
Compound 20 was prepared from intermediate 1 (120 mg. >250° C. The purity of 23 was confirmed using HPLC (95%,
0.625 mmol) and intermediate 11 (213 mg 0.625 mmol) 15 R=18.98). 'H-NMR (DMSO-d6): 83.38-3.82 (br, m, 10H),
following the same procedure utilized in the preparation of 7.21-7.33 (m, 6H), 7.53-7.69 (m, 5H), 7.93 (m, 2H), 8.15 (m.
8.34 (s. 2H), 8.51 (m, 2H), 8.64 (d. J=8.28 Hz, 1H),
13. The product obtained was a white solid (180 mg, 34%); 2H),
10.06 (s, 1H). 'C-NMR (DMSO-d6): 83456, 43.53, 11408,
mp: >250° C. The purity of 20 was confirmed using HPLC
121.28, 122.95, 123.11, 126.16, 127.98, 128.21, 128.38,
114.01, 120.67, 121.79, 122.86, 125.02, 125.97, 127.9,
128.16, 128.27, 128.6, 130.12, 130.2, 133.23, 136.23, 138.3,
139.59, 150.56, 157.03, 157.92, 159.02, 160.3, 169.2. MS:

(96.02%, R=14.823). "H-NMR (DMSO-d6): 8 1.12 (t, 3H),

128.54, 128.6, 128.75, 130.29, 130.42, 131.47, 133.44,
138.19, 140.8, 140.89, 150.57, 157.83, 159, 160.18, 169.19.

2.43 (q, 2H), 3.32-3.78 (m, 8H), 7.51-7.65 (m, 6H), 7.89 (m,
2H), 8.12 (m, 2H), 8.27 (s. 2H), 8.47 (m, 2H), 8.6 (d. J=8.28

MS: calcd 577.26 for CHNOMI. found, 577.69 Mt.
Example 24

HZ, 1H), 10.0 (s, 1H). 'C-NMR (DMSO-d6): 8 15.54, 21.88,

43.59, 114.04, 121.22, 123.07, 124.92, 126.07, 127.91
128.17, 128.47, 130.28, 130.33, 133.36, 138.16, 140.74,
150.53, 157.1, 157.77, 158.94, 160.22, 169.11. MS: calcd

515.24 for C31H NO IMI". found, 515.89 |M|.
Example 21
Preparation of (4-(5-ethylpyrimidin-2-yl)piperazin-

1-yl)(4-((2-phenylduinazolin-4ylamino)methyl)phe
nyl)methanone (21)
Compound 21 was prepared from intermediate 1 (120 mg.
0.625 mmol) and intermediate 12 (221 mg 0.625 mmol)
following the same procedure utilized in the preparation of
13. The product obtained was a white solid (105 mg, 20%);
mp: 207-208°C. The purity of 21 was confirmed using HPLC

25

Compound 24 was prepared from intermediate 2 (120 mg,
0.472
mmol) and intermediate 12 (167 mg, 0.472 mmol)
30 following
the same procedure utilized in the preparation of
13. The productobtained was a white solid (59 mg, 10%); mp:
216-217° C. The purity of 24 was confirmed using HPLC

(97.27%, R=19.543). H-NMR (DMSO-d6): & 3.37-3.79

35

HZ, 1H), 8.44-8.47 (m, 2H), 9.02 (t, J=5.82 Hz, 1H). C

40

8.43 (m, 2H), 8.98 (t, J=5.82 Hz, 1H). 'C-NMR (DMSO

d6): 815.56, 21.88,414, 43.26, 43.56, 46.85, 113.79, 122.68,

124.94, 125.45, 127.24, 127.31, 127.84, 128.2, 130.3,
132.83, 134.26, 138.52, 141.51, 149.98, 157.1, 159.15,

(br, m, 10H), 4.99 (d. J=5.82 Hz, 2H), 7.19-7.31 (m, 5H),
742-7.66 (m, 8H), 7.82 (m, 2H), 8.3 (s. 2H), 8.35 (d. J=8.22
NMR (DMSO-d6): 8 34.51, 43.24, 43.56, 113.79, 122.68,

(97.08%, R=15.735). H-NMR (DMSO-d6): & 1.1 (t, 3H),

2.41 (q, 2H), 3.34-3.76 (m, 8H), 4.97 (d. J=5.82 Hz, 2H),
7.4-7.55 (m, 8H), 7.79 (m, 2H), 8.25 (s. 2H), 8.33 (m. 1H),

Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(4-((2-phenylduinazolin-4-ylamino)methyl)
phenyl)methanone (24)

45

159.59, 160.16, 169.11. MS: calcd 529.26 for C32HNO
M. found, 529.88 Mt.
Example 22
50

Preparation of (4-(5-benzylpyrimidin-2-yl)piperazin
1-yl)(3-(2-phenylguinazolin-4ylamino)phenyl)
methanone (22)

122.88, 125.45, 126.1, 127.23, 127.3, 127.84, 128.2, 128.31,
128.53, 130.04, 132.83, 134.24, 138.52, 140.83, 141.51,
149.98, 157.77, 159.15, 159.58, 160.09, 169.12. MS: calcd

591.27 for CHNOMI". found, 591.69 |M|.
Example 25
Preparation of 4-(4-(5-bromopyrimidin-2-yl)piper
azin-1-yl)-6-fluoroquinazoline (25)
A mixture of 5-bromo-2-(piperazin-1-yl)pyrimidine (240
mg, 1.0 mmol), 4-chloro-6-fluoroquinzoline (180 mg, 1.0
mmol), and diisopropylethylamine (190 mg, 1.5 mmol) in
isopropanol (10 ml) was refluxed at 80° C. for 1.5 hr. The
Solid separated out of the reaction upon cooling and was
filtered, washed with hot solvent and dried to afford com

pound 25 which was obtained as fine white crystals (317 mg,

81% yield). H-NMR (DMSO-d6): 83.8 (m, 4H), 3.9 (m,

Compound 22 was prepared from intermediate 2 (120 mg, 55 4H), 7.75 (m, 2H), 7.88 (dd. 1H), 8.48 (s. 2H), 8.62 (s, 1H).
0.472 mmol) and intermediate 10 (160 mg. 0.472 mmol)
'C-NMR (DMSO-d6): 843.7, 49.0, 106.25, 109.95, 110.15,
following the same procedure utilized in the preparation of 116.9, 117.0, 122.95, 123.15, 148.95, 153.75, 158.2, 158.5,
13. The product obtained was a white solid (135 mg, 23%);
159.85, 159.95, 163.95.
mp: 214-215°C. The purity of 22 was confirmed using HPLC
Example 26
(95.38%, R=18.948). 'H-NMR (DMSO-d6): 83.37-3.83 (br. 60
m, 10H), 7.2-7.32 (m, 6H), 7.44-7.67 (m, 5H), 7.91 (m, 2H),
Preparation of (4-(5-bromopyrimidin-2-yl)piperazin
8.1 (ddd, J=0.9 Hz, J=2.1 Hz, J=8.28 Hz, 1H), 8.2 (m. 1H),
1-yl)(4-(6-fluoroquinazolin-4-ylamino)methyl)phe
8.32 (s. 2H), 8.47 (m, 2H), 8.62 (d. J=8.28 Hz, 1H), 10.0 (s,
nyl)methanone (26)
1H). 'C-NMR (DMSO-d6): 8 34.53, 41.46, 43.84, 46.95,
113.99, 120.65, 121.84, 122.89, 122.98, 123.02, 126.07,
126.11, 127.88, 128.17, 128.33, 128.54, 128.66, 128.78,
130.3, 131.43, 132.01, 133.34, 136.11, 138.18, 139.54,
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Compound 26 was prepared from 4-chloro-6-fluoroquin
Zoline (11 mg, 0.06 mmol), following the same procedure

US 8,609.672 B2
37
utilized in the preparation of 13. The product 26 obtained was

a pale yellow solid (19 mg, 60%). "H-NMR (DMSO-d6): 8

3.33-3.84 (brm,8H), 4.84 (d. J=6.6 Hz, 2H), 7.37 (d. J=9 Hz,
2H), 7.41 (d. J=9 Hz, 2H), 7.68 (ddd, J=3 Hz, J=8.4 Hz, J=9
HZ, 1H), 7.76 (dd, J=6.6 Hz, J=9 HZ, 1H), 8.14 (dd, J=3.6 Hz,
J=9 HZ, 1H), 8.34 (s, 1H), 8.35 (s, 1H), 8.43 (s, 1H), 8.81 (t,
J=6 Hz, 1H).
Biological Methods
Growth Inhibition of NCI-60 Tumor Cell Lines

The NCI-DTP uses the SRB (sulforhodamine B) assay to
measure the ability of a test compound to inhibit the growth of
a given cell line. The cell lines used in the NCI-60 are main
tained using RPMI 1640 medium supplemented with 5% fetal
bovine serum and 2 mM L-glutamine. Cell lines are seeded
into a series of 96-well microtiter plates, with varied inocu
lation densities, depending on the growth rate and doubling
time of each cell line. The plates are then incubated at 37°C.,
5% CO, 95% air and 100% relative humidity for 24 hours
before treating with the test compounds. On the treatment
day, experimental agents are added to the cells with a series of
target final concentrations: 100, 10, 1, 0.1, and 0.01 uM. After
48 hours treatment while being incubated under the above
conditions, the cells are fixed with trichloroacetic acid (con
centration differs according to the nature of the cell line:
adherent or suspension) for one hour at 4°C. After removal of
the Supernatant, the plates are washed with water several
times and dried completely in the air. Then 100 uL of 0.4%
sulforhodamine B (SRB) solution in 1% acetic acid is added
for 10 minutes. The unbound dye is removed and the plates
are washed with 1% acetic acid. The bound dye is then solu

5

10

15

25

30

bilized with 10 mM trizma base, and the absorbance is mea

sured using a plate reader at 515 nm. The same treatment and
measurement were performed for cells prior to treatment and
were assigned TZ (T-zero). The % growth was calculated
using the following equation:
% growth =

% growth = 50 =

35

40

signal-positive
control signal)
B-Poc=1 test compound
p
gnal-p
gnal) xx 100
100
(negative control signal-positive control signal)

50

treatment time and calculated from
(T-T)x100
T.
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MTT Viability Assay
MDA-MB-468 human breast cells were obtained from

ATCC and cultured in RPMI 1640 medium (ATCC) supple
mented with 10% FBS (Invitrogen), and 2% antibiotic-anti
mycotic mixture of Penicillin-G, Streptomycin sulfate, and
Amphotericin B (Invitrogen) in a 5% CO-95% humidity
incubator at 37° C. 3-4,5-dimethylthiazol-2-yl)-2,5-diphe
nyltetrazoliumbromide (MTT) assay was chosen to deter
mine the IC50 (the concentration required to inhibit survival
by 50%) of the test compounds (4, 15, and 16) against the

buffer (PBS, 0.05% Tween 20), and then incubated with elu
tion buffer (PBS, 0.05% Tween 20, 0.5 M non-biotinylated
kinase ligand) and eluted. The kinase concentration in the
eluate was then measured by quantitative PCR. The detected
signal is proportional to the number of eluted DNA-tagged
kinase molecules and hence to the binding potency of a given
test compound. The results of this single dose screening are
reported in the form of binding percentage of control
(B-POC) which is defined as follows:

45

(T-T)x100
(C-T)

TGI is the dose that causes a total inhibition of the growth and
can be computed using the equation: Ti-TZ. LC50 is the dose
that kills 50% of the cells compared to the cell density at the

each well to dissolve the formed formazone crystals. Plates
were kept at room temperature over night away from light.
The optical density of the formed violet color was quantified
using an automatic spectrophotometer (Tristar LB 941) at a
wavelength of 562 nm. The experiment was carried out with
triplicate for each concentration of a given compound. Three
independent experiments were conducted at three different
dates. The concentration required for 50% reduction in the
optical density, and hence the viability compared to control
vehicle treated wells, was estimated for each compound
against the studied cell line by non-linear regression analysis
of the Log 10 concentration in moles versus % viability
curves. Curve fitting was performed using the variable slope
four parameter module implemented in the GraphPad Prism
software (version 5.02).
Kinase Binding Screening
Biotinylated kinase ligand was immobilized onto Strepta
vidin coated magnetic beads and washed with blocking
buffer. The liganded beads were then incubated with DNA
tagged kinase in the presence of test compound for 1 hat room
temperature. Binding reactions were carried out in 20%
Seablock, 0.17xPBS, 0.005% Tween 20, 6 mMDTT, in a final

(C-T)

where Ti is the reading for the treated well after two days of
the treatment with a certain concentration of a specific com
pound. C is the average reading measured in the untreated
wells after two days of treatment with the vehicle. TZ is the
average reading measured prior to treatment. GI50 is the dose
that causes 50% inhibition of the growth after the treatment
time compared to the TZ and calculated from

then incubated for 4 hours under 10% CO2 at 37° C. The
media was then removed and 100 uL of DMSO was added to

Volume of 0.04 mL. Beads were then washed with wash

(T-T)x100

gr
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MDA-MB-468 cell line using gefitinib as a positive control.
5000 cells, in 100 uL of the culture medium, were plated per
well in 96-well plates. Cells were allowed to adhere for 1 day.
Cells were then treated with fresh culture medium containing
one of several concentrations of the test compounds; 100, 10.
1, 0.1, 0.01, 0.001 uM. The plates were processed after 48,72,
or 120 hours via discarding the media and adding 100 uI, 0.5
mg/ml MTT reagent in fresh culture media. The plates were
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The negative control signal is obtained by the vehicle and
corresponds to B-POC=100%. The positive signal control is
detected by a binding positive compound and is B-POC 0%.
The B-POC results are the average of duplicate measure
ments. Only interactions with B-POC-35 were considered
significant and thus used for calculating the selectivity Scores
(Table 1) of the test compounds as follows:
number of kinases showed B-POCs 35
S(35) = - - - - -

(35) total number of wild-type kinases(198)

In order to determine the Kd, the above procedure is followed
at 11-point three fold serial dilution of the test compound,
from 30 M to 0.508 nM, with the result of a standard dose
response curve. The Kid is then calculated according to the
following equation:

US 8,609.672 B2
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In Vitro Cellular Screening
signal-background
Compounds 3-6 and 13-24 were screened in-house against
response = background+ .
.
. . . .
A549 (NSCLC) and MCF7 (breast cancer) cell lines to test
1 + K P + dosehill slope
the target compounds cytotoxic potential and to reduce the
hill slope=-1. A non-linear least square fit with the Leven 5 number of compounds to be further investigated (data not
berg-Marquardt algorithm was implemented to fit the curves shown). The structures of the active compounds were submit
(FIG. 3). Kinase binding assays were performed by Ambit ted for screening against the NCI-60 cell lines panel. Com
Bioscience (San Diego, Calif., USA).
pounds (3-4, 13, 15-16, and 19-23) were initially accepted for
The results of kinase binding assay are shown in Table 1,
screening against the NCI-60 at a single concentration of 10
which includes the B-POC values of 10M of compounds 4, 10 uM. Eight out of the above compounds (3-4, 13, 15-16, and
15, and 16 against the most sensitive kinases tested within this
19-21) showed significantantiproliferative activity at a 10uM
binding experiment. Kinases are ranked according to their dose and were accordingly evaluated at five concentrations in
sensitivity towards binding by each compound separately order to determine their dose-response behavior and calculate
from the most (lower B-POC) to the least (higher B-POC) their GI50 (dose inhibiting 50% of the growth compared to
sensitive. Kinases within the same subfamily are highlighted. 15 the control), TGI (dose inhibiting the growth completely),
Selectivity scores (S35) of the test compounds against a total and LC50 (dose killing 50% of the starting cell population)
of 198 wild-type non-mutant kinases. K values of 4 against
selected PDGFR subfamily members are in parentheses and
expressed in uM. Both the B-POC and K values are the
average of duplicate measurements.

values. Table 2 shows the GI50, TGI, and LC50 values for
compounds 4, 15, and 16. Three compounds (3-4 and 15)
showed an interesting pattern of cytotoxic activity and were
submitted for retesting in order to confirm the reproducibility

TABLE 1

B-POC (K)
Kinase
CEOK

4
O

Kinase
15
ABL1(F317L)- 6.8

phosphorylated
0.5 (0.11) BRAFV600E 13

3.4
3.5
4
4.1
4.3

RIPK1

Kinase
RIPK1

ABL1(F317L)- 20
phosphorylated
22
23
25
28
43

23

24
29
34

8.4 (0.53)
9.1 (2.5) CDK. 47

Subfamily

9.8
21
26
30

CDK
PDGFR
DDR
CK1
ABL

30 (1.3)
31
45
46
47
49

Number of kinases with B-POC is 35 15
S(35)
O.075

p38
RIPK

7

Functional Kinase Inhibition Assay
This experiment was conducted by mixing the test kinase,
10 uM Y-33P-ATP, positively charged substrate, magnesium
acetate, 1 uM test compound, and reaction buffer at room
temperature. The reaction is then stopped by the addition of
phosphoric acid solution. 10 uL of the reaction is filtered
through a P30 filament, washed properly, dried, and finally
Subjected to Scintillation counting. The inhibition of a given
kinase is represented by the function percentage of control
(F-POC) which is calculated as follows:
F-POC =

19 19

mean(counts - blanks).
test X 100
mean(counts - blanks) negative control

The assay was performed in duplicates. Dose-response
curves were fitted using nonlinear regression as implemented
in GraphPad Prism software (version 5.02). A Sigmoidal
dose-response (variable slope) was used in this case (FIG. 4).
Kinase inhibition assays were performed by Millipore Corp.
(Dundee, UK).
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of their cellular actions. The three compounds gave reproduc
ible results, and compound 15 was chosen Subsequently by
the DTP-BEC (Developmental Therapeutic Program-Bio
logical Evaluation Committee) to advance to the MTD
(Maximum Tolerated Dose) testing in vivo. According to the
NCI-anticancer Screening paradigm, if 15 is safe in healthy in
vivo models, it will be further subjected to the in vivo hollow
fiber assay, and possibly human tumor Xenografts in an
attempt to measure its in vivo anticancer potential (Shoe
maker, R. H. Nature Reviews Cancer 2006, 6, 813-823; Ske
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han, P. et al. Journal of the National Cancer Institute 1990,
82, 1107-1112: Takimoto, C. H. Cancer Chemotherapy and
Pharmacology, Supplement 2003, 52).
The GI50 (dose inhibiting 50% of the growth compared to
control), TGI (dose inhibiting the growth completely), and
LC50 (Dose killing 50% of the starting number of cells)
values result from screening of compounds 4, 15, and 16
against the NCI-60 cell line panel after 48 hours treatment are
shown in Table 2. All values are given in LM. Cells high
lighted in bold have values: 0.1<GI50s1 uM.

US 8,609.672 B2
TABLE 2-continued
Cell line
4

BT-549
T-47D
MDA-MEB-468
Mean

15

16

GIso

TGI

LCso

GIso

TGI

LCso

GIso

TGI

LCso

1.26
0.71
0.06
5.24

18.40
45.5O
2.73
37.15

43.OO
>100
>100
81.28

0.34
1.25
0.03
4.46

10.70
>100
2.22
S128

>100
>100
>100
>100

0.44
0.24
0.74
105

174
7.59
3.47
3.24

5.37
S.62
-100
22.91

Compound 16 (NSC: D-750776) shows the highest overall
potency and non-selectivity against the cell lines and it does
not display a significant difference between its cytostatic
markers (mean GI50=1.05uM and mean TGI-3.24 uM) and
cytotoxic indicator (LC50=22.91 uM). These data could be
projected into potential toxicity against normal cells resulting
in a narrow therapeutic index. On the other hand, 4 (NSC:
D-750901) and 15 (NSC: D-750905) display a pattern of
selective cytostatic potency against certain cell lines scattered
among different tissues of origin. For example, 15 is potent
against RPMI-8226 (leukemia, G150–68 nM), NCI-H23
(lung, GI50–90 nM), SK-MEL-5 (skin, GI50–61 nM), and
MDA-MB-468 (breast, GI50–30 nM) cancer cell lines. These
two derivatives, 4 and 15, also show a significant difference
between their cytostatic markers (mean GI50 & mean TGI)
and cytotoxic indicator (mean LC50). These data may clas
Sify 4 and 15 as cytostatic compounds whereas 16 may be
described as a cytotoxic agent. According to the data pre
sented in Table 2, and the testing reports obtained from the
NCI-60 screening, the relationships between the structure
variations of the piperazinylpyrimidine derivatives and their
cytostatic/cytotoxic activities can be summarized as shown in
FIG. 5. A benzyl group in the 5-position of pyrimidine ring
may lead to more antiproliferative activity compared to ethyl
substitution. Derivatives based on 2-phenylquinazoline based
derivatives show overall weaker antiproliferative potential
compared to the quinazoline based derivatives. Concerning
the linkers in group II compounds, the para orientation shows
the least cytotoxic activity whereas the metapositioning leads
to the most potent derivatives (e.g., compound 16). Incorpo
ration of a flexibility inducing element may have refined the
series into the selective cytostatic performance of 15. Without
being bound by any theory, the correlation between the cel
lular profile of 4 (group I) and 15 (group II) in both terms of
cellular selectivity and cytostatic rather than cytotoxic action
raises the hypothesis that they both can affect similar set of
targets in the cell and that 15, through its flexible methylene
group, is able to attain a conformational ensemble very simi
lar to those attained by the more rigid derivative, 4, devoid of
any linkers.
The concentration and time dependencies of the antipro
liferative activity of compounds 4, 15, and 16 against MDA
MB-468 cell line were further investigated using MTT assay.
This cell line represents the triple negative/basal like breast
carcinoma which is usually accompanied by frequent
relapses and poor survival, reflecting the need for efficient yet
safe agents to be used in this specific clinical setting. The
MDA-MB-468 cell line is also sensitive to DNA-damaging
agents which are known to be highly toxic and non-selective
(Oliveras-Ferraros, C. et al. International Journal of Oncol
ogy 2008, 33, 1165-1176). MDA-MB-468 cell line is known
to overexpress EGFR receptor (Nautiyal, J. et al. Molecular
Cancer Therapeutics 9, 1503-1514.). Therefore, gefitinib,
known as an EGFR inhibitor, was included in the study as a

15

positive control. According to the dose-response curves
shown in FIG. 6, the antiproliferative activity of a given test
compound is directly proportional to the treatment time and
the concentration. The ranking of activity according to the
obtained IC50 values is as follows: 4 and 15 are more anti
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proliferative than 16 than gefitinib.
Kinase Profiling of 4, 15, and 16
The compounds of the present invention were structurally
designed with the intention to interfere with certain members
of the humankinome. Compounds 4, 15, and 16 were selected
because they represent the three major structural variations
and also because they were either selective cytostatic or
potent cytotoxic on the cellular level. Compound 4 represents
the direct attachment of the quinazoline ring with the piper
azinylpyrimidine Scaffold (group I). Compound 15 exempli
fies the use of a flexible linker whereas compound 16 has a
more rigid incorporated linker and both belong to group II
(FIG. 1). Two different kinase experiments were chosen for
the current study. One is classified as a binding or non-bio
chemical testing while the other is functional and biochemi
cally oriented.
In order to test the potential of 4, 15, and 16 to bind with the
humankinome to which they were designed to target, a kinase
binding assay was used to examine the ability of 10 uM of 4.
15, or 16 to interfere with the binding of a given kinase with
an immobilized, ATP directed agent (Karaman, M. W. et al.
Nature Biotechnology 2008, 26, 127-132; Fabian, M.A. et al.
Nature Biotechnology 2005, 23, 329-336; Pettus, L. H. et al.
Journal of Medicinal Chemistry 2010, 53,2973–2985; Ander
sen, C. B. et al. ACS Chemical Biology 2008, 3, 180-192:
Jiang, J. K. et al. Journal of Medicinal Chemistry 2008, 51,
8012-8018: Burns, C. J. et al. Bioorganic and Medicinal
Chemistry Letters 2009, 19, 1206-1209; Chao, Q, et al. Jour
nal of Medicinal Chemistry 2009, 52, 7808-7816.). A single
dose of 10 uM was chosen to allow for detecting kinases able
to bind to the test compounds. In this binding assay, a set of
243 kinases were included. This set of kinases coversi) wild
type Versus mutant kinases; and ii) phosphorylated versus
non-phosphorylated set of either wild-type or mutant ABL1
kinases (Table 3). Table 4 lists the kinases tested. A given
interaction is represented by a numerical value called binding
percentage of control (B-POC). The lower the B-POC value,
the stronger the test compound binds with the test kinase.
Only results with B-POCs50 are shown in Table 1 and are
highlighted based on the kinases subfamilies, which aids in
detecting the selectivity of the test compounds for being
prototype inhibitors of certain kinase subfamilies. The
kinases are ranked from the most to the least sensitive kinase

towards binding with a given test compound. Table 1 illus
trates that within the set of tested kinases, certain members of
65

CDK, CK1, PDGFR, DDR, ABL, p38, RAF, or RIPK sub
families are more or less recognized by the three test com
pounds. Some members of CK1 subfamily are commonly
recognized by the three test compounds. Compound 15 shows
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almost equal affinity to bind to several members of CK1
subfamily whereas CSNK1D is almost equivalently sensitive
to the three derivatives: B-POC-26 against 4, B-POC–23
against 15, and B-POC-22 against 16. Another CKI member,
CSNKIE, is found to be sensitive towards 15 and 16 more

than towards 4. CSNKIE is found to be significantly
expressed in several cancer types compared to their normal
tissues (Yang, W. S.; Stockwell, B. R. Genome Biology
2008). Without being bound by any theory, the above results
suggest that for CK1 subfamily members, the combination of 10
piperazinylpyrimidine
scaffold with quinazoline ring may be
-0

46
tionally, compound 15 binds with higher affinity to BRAF and
its common V600E mutant whereas 4 and 16 are recognized
by RIPKI, another TKL (tyrosine kinase like) kinase. Among
the tested unphosphorylated and phosphorylated derivatives
of ABL1, only two close mutants are bound by the test com
pounds.

relevant for binding irrespective to the presence of linkers or

TABLE 3

Phosphorylated

Non-phosphorylated

Wild-type

1

198

Mutants

8

36

a specific linker. Accordingly, CK1 family kinases, especially
CSNK1D, may contain a common binding site which is able
TABLE 4
Description

Kinases

Wild-type Phosphorylated
ABL1-phosphorylated
Non-phosphorylated ABL1, ABL2, ACVR1, ACVR1B, ACVR2A, ACVR2B,
ACVRL1, ADCK3, ADCK4, AKT1, AKT2, AKT3, ALK,
AURKA, AURKB, AURKC, AXL, BLK, BMPR1A,
BMPR1B, BMPR2, BMX, BRAF, BRK, BTK, CAMK2B,
CDC2L1, CDC2L2, CDC2L5, CDK11, CDK2, CDK3, CDK4

cyclinD1, CDK4-cyclinD3, CDK5, CDK7, CDK8, CDK9,
CDKL1, CDKL2, CDKL3, CDKL5, CHEK1, CHEK2, CLK3,
CSF1R, CSK, CSNK1A1, CSNK1A1 L, CSNK1D, CSNK1E,
CSNK1G1, CSNK1G2, CSNK1G3, CSNK2A1, CSNK2A2,
CTK, DAPK1, DAPK2, DAPK3, DCAMKL1, DDR1, DDR2,
DYRK1B, EGFR, EPHA2, EPHA3, EPHA6, EPHA8, EPHB2,
EPHB3, EPHB4, ERK1, FAK, FER, FES, FGFR1, FGFR2,
FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FRK, FYN,

GSK3A, GSK3B, HCK, IGF1R, IKK-alpha, IKK-beta, IKK
epsilon, INSR, INSRR, ITK, JAK1(JH1domain-catalytic),
JAK2(JH1 domain-catalytic), JAK3(JH1domain-catalytic),
JNK1, JNK2, JNK3, KIT, LCK, LKB1, LTK, LYN, MAP3K1,
MAP3K15, MAP3K2, MAP3K3, MAP3K4, MAP4K2,
MAP4K3, MAP4K4, MAP4K5, MAPKAPK2, MARK3,
MEK1, MEK2, MERTK, MET, MKNK1, MKNK2, MLK1,

MST1R, MTOR, MUSK, NEK1, p38-alpha, p38-beta, p38
delta, p38-gamma, PAK1, PAK2, PAK3, PAK4, PAK6, PAK7,
PCTK1, PDGFRA, PDGFRB, PDPK1, PIK3C2B, PIK3CA,

PIK3CG, PIM1, PIM2, PIM3, PKAC-alpha, PLK1, PLK2,
PLK3, PLK4, PRKCE, PRP4, PYK2, RAF1, RET, RIOK1,
RIOK2, RIOK3, RIPK1, RIPK2, RIPK4, ROCK2, ROS1,

RSK2(Kin. Dom.1-N-terminal), SNARK, SRC, SRMS, SRPK3,
STK39, SYK, TAK1, TEC, TGFBR1, TGFBR2, TIE1, TIE2,
TNIK, TNK1, TNK2, TNNI3K, TRKA, TRKB, TRKC,

TSSK1B, TXK, TYK2(JH1domain-catalytic), TYRO3, ULK2,
Mutants

Phosphorylated

VEGFR2, VRK2, WEE1,YANK3, YES, ZAP70

ABL1(E255K)-phosphorylated, ABL1 (F317I)-phosphorylated,
ABL1 (F317L)-phosphorylated, ABL1(H396P)-phosphorylated,
ABL1(M351T)-phosphorylated, ABL1 (T315I)-phosphorylated,
ABL1(Y253F)-phosphorylated, ABL1(Q252H)-phosphorylated,
Non-phosphorylated ABL1 (F317I), ABL1 (F317L), ABL1(H396P), ABL1(Q252H),

to accommodate piperazinylpyrimidine derivatives of differ
ent molecular sizes and linkers.

Compound 4 exhibits obvious tendency to bind strongly
with certain wild-type and/or mutant members of the CDK
and PDGFR subfamilies. Without being bound by any theory,
the binding of compound 4 could be attributed to sterics, as 4
is smaller in size than both 15 and 16 and that the targeted
binding site of these subfamilies, CDK and PDGFR, is unable
to accommodate these larger derivatives (15 and 16). Addi

ABL1 (F317I) is moderately recognized by 4 (B-POC-30)
60 and 16 (B-POC-20) whereas ABL1 (F317L) is more strongly
recognized by 15 (B-POC-6.8). Since phosphorylated
kinases are presumed to exist preferentially in the active state,
the data Suggest that the test compounds interact with active
kinases and inhibit their phosphotransferase function.
65 Accordingly, a biochemical functional screening of the test
compounds was pursued. Compound 4 is able to target
PDGFR wild-type and mutants without affecting ABL1 or
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ABL2 kinases (only phosphorylated ABL1 (F317I) mutant
was targeted by 4). It is common for inhibitors binding to the
ABL subfamily to also target the PDGFR subfamily and vice
versa (See e.g., imatinib. Cohen, M. H. et al. Clinical Cancer
Research 2002, 8,935-942; Dagher, R. et al. Clinical Cancer
Research 2002, 8, 3034-3038). Compound 4 represents a

48
TABLE 5-continued
Description

Kinases

5

structure that can discriminate between PDFGR and ABL

subfamilies. Only interactions with B-POCs35 were consid
ered significant and thus used for calculating the selectivity
scores of the test compounds (Table 1, FIG. 2). The test
compounds, as prototype kinase binders, have excellent over
all selectivity towards certain kinase subfamilies. Based on
the results of this primary single-dose screen, the concentra
tion-dependent potential of compound 4 to bind to FLT3,
KIT, KIT(D816H), or KIT(D816V) was investigated. The Kd
(dissociation constant) of the four interactions was deter
mined (Table 1). Dose responsecurves of compound 4 against
FLT3, KIT, KIT(D816H), or KIT(D816V) are shown in FIG.

10

TABLE 6

F-POC (ICso)
15

3.

In order to evaluate whether the molecules could inhibit the

phosphotransferase kinase function a radiometric based assay
was used to measure the ability of 1 uM of compounds 4, 15,
or 16 to interfere with the function of a set of 55 protein
kinases; 39 wild-type and 16 mutants (Table 5) (Davies, S. P.
et al. Biochemical Journal 2000, 351, 95-105; Copeland, R.
A. Analytical Biochemistry 2003, 320, 1-12). This set of
tested kinases was chosen based on the results of the binding
assay described above. Again the ability of 1 uM of a given
test compound to inhibit the phosphotransferase function of a
given kinase is expressed by functional percentage of control
(F-POC) value which is also inversely proportional to the
potency of the test compound, at that specific concentration,
for a given kinase. The most promising interactions, at a
single dose, were further investigated to determine the IC50
values. The IC50 of compound 4 was determined against KIT,
KIT(D816H), KIT(D816V), KIT(V560G), FLT3, PDGFRA
(V561D), and PDGFRA(D842V) (Table 6). The results of
kinase function inhibition assay are shown in Table 6, includ
ing the F-POC of 1 uM of compounds 4, 15, and 16 against the
most sensitive kinases tested within this experiment. Kinases
are ranked according to their sensitivity towards binding by
each compound separately from the most (lower F-POC) to
the least (higher F-POC) sensitive. Kinases within the same
subfamily are highlighted. The IC50 values of compound 4
against a set of PDGFR subfamily selected kinases and
mutants are in parentheses and expressed in M. Both the
F-POC and ICs values are the average of duplicate measure
ments. Dose-response curves were used to determine the
IC50 values (FIG. 4).
The three test compounds, weakly inhibit the same mem
ber of CK1 subfamily, CSNK1D. Compound 4 demonstrates
the ability to inhibit the function of some PDGFR subfamily
members; both wild-type and mutants, without affecting ABL
subfamily members. On the other hand, 15 and 16 show weak
inhibitory action over ABL kinase and some members of
PDGFR subfamily.
Kinases

Kinase

15

Kinase

16

PDGFRA(V561D)

20 (0.295)

ABL

80

MAPK1

73

PDGFRA(D842V)
KIT(D816H)
KIT(V560G)

25 (0.316)
30 (0.316)
36 (0.699)

FLT3
PKBB

80
74
82 PKBB
83
87 KIT(V560G) 86

FLT3
MET

74 (6.692)
75

AB.

KITCD816V)

83 (2.823)

PKB

PKBf

89

PDGFR

90

CK1
ABL

94 (>10.0)

87

Subfamily

25

Both kinase profiling experiments, binding and functional,
revealed that compound 4 shows more potential to either bind
to or inhibit the function of Some of the KIT and PDGFRA
30

mutants compared to their wild-type isoforms. The B-POC of
10 uM and F-POC of 1 M of compound 4 measured in the
binding and function inhibition experiments, respectively, are
shown in Table 7. The location of each mutation is included
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Wild-type (39) Abl, CDK2/cyclinA, CDK2, cyclinE, CDK6/cyclinD3,
CK1, CK18, CK2, CK2C2, cKit, c-RAF, c-SRC, DDR2,
EGFR, FGFR1, Flt3, IKKC., IKKB, JAK2, JAK3,
JNK1C1, JNK2O2, JNK3, MAPK1, MAPK2, MEK1,

Met, mTOR, p70S6K, PAK5, PDGFRC, PDGFRB,
PDK1, PI3K/p85c., PI3K/p65C., PKBC, PKBB,
PKBY, RIPK2, SAPK3

4

KIT

TABLE 5
Description

Kinase
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(Gajiwaia, K. S. et al. Proceedings of the National Academy
of Sciences of the United States of America 2009, 106, 1542–
1547: Heinrich, M. C. et al. Science 2003, 299,708–710.). It
has been reported that different gain-of-function mutations of
the KIT kinase lead to constitutive catalytic activity indepen
dent of activation by extracellular stem cell factor. The occur
rence of these mutations was detected in cases where mar

keted KIT inhibitors (imatinib, dasatinib and Sunitinib) face
resistance by the target cancer cells and become inefficacious
in the treatment of chronic myeloid leukemia (CML) and/or
gastrointestinal stromal tumors (GIST) (Gajiwaia, K. S. et al.
Proceedings of the National Academy of Sciences of the
United States of America 2009, 106, 1542–1547: Masson, K.:
Ronnstrand, L. Cellular Signalling 2009, 21, 1717-1726;
Bougherara, H. et al. Molecular Cancer Research 2009, 7.
1525-1533). Compound 4 shows higher activity against the
KIT A-loop mutants; D816H and D816V compared to its
activity against wild-type KIT which is supported by both the
Kd values in the binding screen and the IC50 values in the
functional assay. As common with many other kinase inhibi
tors, mutations in the gatekeeper of KIT could render the
protein less liable to binding by 4; an observation reinforced
by the increase in the B-POC value of the juxtamembrane
mutant KIT(V559D) upon mutation of the gatekeeper in the
double mutant KIT(V559D, T670I). Without being bound by
any theory, this may suggest that the gatekeeper residue and
probably the adjacent hinge region are critical in binding of 4
to KIT. It is clear that 4 can bind the KIT(D816V) (Kd=0.11
uM) more than it binds KIT(D816H) (Kd=1.3 uM), whereas
it inhibits the function of KIT(D816H) (IC50=0.316 uM)
more than it inhibits KIT(D816V) (IC50=2.82 uM). Such
opposite effects, on two different mutations at the same loca
tion, may originate from the difference in the preferred con
formational ensembles. Also, this highlights the potential
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effect of a single amino acid mutation upon the probability
distribution of the protein's conformations to be selected for
binding by a given small molecule like 4. The ability of
compound 4 to efficiently bind to certain KIT mutants, that

50
tal conditions, is shown in Table 8 (Karaman, M. W. et al.
Nature Biotechnology 2008, 26, 127-132). The K values of
the reference kinase inhibitors were determined experimen
tally against the two kinases similarly to that of 4 and were
obtained from literature. AAG, as a measure of the differen

are resistant to other kinase inhibitors, more than it binds to

the wild-type suggest that 4 can be selective towards cancer
phenotypes harboring and depending on Such mutant KIT
forms versus normal cells depending mainly on wild-type
KIT to function. Compound 4 also exhibits a similar fashion
of selectivity towards certain PDGFRA mutants (V561D in
the juxtamembrane or D842V in the A-loop) as illustrated by

10

the F-POC and IC50 determination. Such PDGFRA mutants
exhibit differential resistance towards certain kinase inhibi
tors like imatinib and nilotinib and become common in cer

tain forms of resistant cancer phenotypes (Heinrich, M. C. et
al. Science 2003, 299, 708–710; Liegl-Atzwanger, B. et al.

The data in Table 8 show that the seven reference kinase
15

Virchows Archiv 2010, 456, 111-127; Pasini, B. et al. Journal

of Clinical Endocrinology and Metabolism 2007, 92, 3728
3732:Weisberg, E. et al. Gastroenterology 2006, 131, 1734
1742).

Kinase

Location

KIT(D816V)
KIT(D816H)
KIT(A829P)
KIT(V559D)
KIT(L576P)

A-loop
A-loop
A-loop
JM
JM

B-POC
O.S
30
84
4.3
9.8

O.11
1.3
ND
ND
ND

83
30
ND
ND
ND

2.82
O.316
ND
ND
ND

KIT(V559D, T67OI) JM and GK

66

ND

ND

ND

KIT(V560G)
KIT

JM
Wild-type

ND
9.1

ND
2.5

36
94

O.699
-10.O

PDGFRA(V561D)
PDGFRA(D842V)
PDGFRA

JM
A-loop
Wild-type

ND
ND
21

ND
ND
ND

2O
25
116

O.295
O.316
ND

inhibitors that have negative AAG are known to be type-I
kinase inhibitors which bind to the same binding site occu
pied by ATP (Fedorov, O. et al. Proceedings of the National
Academy of Sciences of the United States of America 2007,
104, 20523-20528; Rixe, O. et al. Cancer Chemotherapy and
Pharmacology 2009, 64, 1139-1148: Weisberg, E. et al.
Blood 2008, 112,5161-5170; Baumli, S. etal. EMBOJournal
2008, 27, 1907-1918; Yun, C. H. et al. Cancer Cell 2007, 11,

TABLE 7
ICso
K (IM) F-POC (M)

tial binding potential against the mutant KIT(D816V) versus
the wild-type KIT, was calculated according to the literature
(Kolb, P. et al. Journal of Medicinal Chemistry 2008, 51,
1179-1188: Abdul Hameed, M. D. M. et al. Journal of Physi
cal Chemistry B 2006, 110,26365-26374). A negative AAG
indicates preferential binding to the mutant whereas a posi
tive AAG indicates increased resistance by the mutant
against the specific inhibitor.

25

30

35

JM = juxtamembrane domain;
GK = gatekeeper residue;

217-227: Boggon, T. J. et al. Blood 2005, 106, 996-1002:
Stamos, J. et al. Journal of Biological Chemistry 2002, 277,
46265-46272). The above observation matches with several
published computational as well as experimental reports
demonstrating that an aspartic acid to Valine mutation in the
position 816 of KIT destabilizes the inactive (DFG-out) con
formations of KIT. The same mutation would consequently
decrease the binding to type-II kinase inhibitors which
mainly bind preferentially to the inactive (DFG-out) confor
mational ensemble of KIT. In addition, the experimental ten
dency of 4 to bind better to the V816KIT compared to the
D816KIT suggests that 4 may be a type-I kinase inhibitor that
targets the ATP binding site in contrast to type-II inhibitors
which exploit the adjacent allosteric binding site.

ND = not determined.

TABLE 8

Compound 15 demonstrates a similar trend of selectivity
towards the mutant BRAF(V600E) versus the wild-type
BRAF (Table 1). BRAF(V600E) mutant is commonly found
in several kinds of cancer especially melanoma and GIST.
This mutation has attracted the attention of research groups to
develop specific inhibitors against it (Liegl-Atzwanger, B. et
al. Virchows Archiv 2010, 456, 111-127; Suijkerbuijk, B. M.
J. M. et al. Journal of Medicinal Chemistry 2010, 53, 2741
2756). ABL1 mutants have been generally shown to affect the
sensitivity towards ABL kinase inhibitors. Point mutations in
codon 317 of ABL1 have been found to specifically impart
resistance towards dasatinib. 58-60 Compound 4 and 16 have
moderate affinity to bind to the phosphorylated form of ABL1
(F317I) while 15 has stronger binding affinity towards the
phosphorylated form of ABL1(F317L).
As revealed by Table 1 and Table 6, although compounds 4
and 15 have certain common kinase targets, they do not share
an overall similar selectivity profile in that 4 is more active
towards the PDGFR subfamily. This is contrary to the corre
lation of their cellular profile against the NCI-60 panel of
cancer cells. One possible scenario is that 4 and 15 could
equally inhibit other protein(s) that belong to a different pro
tein family other than protein kinases. It also may be possible
that 4 and 15 target the same signaling transduction pathway
at different points.
The observed binding affinity of 4 against the wild-type
KIT and its D816V mutant, obtained from the binding data, to
the respective binding affinity of 38 kinase inhibitors against
the same two kinases observed under very similar experimen

K (nM

40

Kinase inhibitor
Staurosporine
45

50

55

60

65

KIT
19

KIT(D816V)
O.64

AAG
-2.01

PKC-412
4
LY-333531
Erlotinib
Gefitinib

220
2SOO
>1OOOO
>1OOOO
>1OOOO

7.7
110
920
1600
43OO

-1.98
-1847
<-1.4
<-1.08
<-049

Flavopiridol

>1OOOO

CI-1033
ZD-6474
VX-680
JN-7706621
Dasatinib
Sorafenib
MLN-518
CHIR-265
ABT-869
Imatinib
BIRB-796
AST-487
AMG-7O6
GW-78.6034
CHIR-258

AZD-1152HQPA
SU-14813
Sunitinib
PTK-787
BMS-387O32
CP-690550
CP-724714
EKB-569

4600

<-0.45

7800
260
240
1800
O.62
31
2.7
2OO
2
14
170
5.4
3.7
2.8
7.5

3900
290
290
2SOO
2.6
310
29
62OO
81
82O
>1OOOO
360
410
500
14OO

-0.41
O.O6
O.11
O.19
O.85
1.36
140
2.03
2.19
2.41
>241
2.48
2.78
3.07
3.09

17

4600

3.31

340
380
>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO

3.68
4.10
>4.48

O.68
0.37
S.1
>1OOOO
>1OOOO
>1OOOO
>1OOOO

US 8,609.672 B2
51

52
junction 'or' should not be read as requiring mutual exclu
sivity among that group, but rather should also be read as
“and/or unless expressly stated otherwise. Furthermore,
although items, elements or components of methods and
compositions described herein may be described or claimed
in the singular, the plural is contemplated to be within the
Scope thereof unless limitation to the singular is explicitly
stated. The presence of broadening words and phrases such as

TABLE 8-continued
Kai (nM
Kinase inhibitor
GW-2580

KIT

KIT(D816V)

>1OOOO

>1OOOO

Lapatinib

>1OOOO

>1OOOO

MLN-8054
PI-103
Roscovitine
SB-2021.90
SB-2O358O
SB-431542
VX-745

>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO

>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO
>1OOOO

AAG

10

“one or more.” “at least,” “but not limited to,” “in some

embodiments, or other like phrases in some instances shall
not be read to mean that the narrower case is intended or

required in instances where such broadening phrases may be
absent.

AAG (Kcal mol) = Rx TX ln K(mutant), K(wild-type) where R = 0.001985 Kcal
mol K and T = 298°K.
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ENUMERATED EMBODIMENTS

Treatment of Breast Tumor Cell Line MDA-MB-468 with

Compound 15

The following enumerated embodiments are representa
tive of some aspects of the invention.
1. A compound of formula (I), (II), or (III):

Treatment of the breast tumor cell line MDA-MB-468 with

compound 15 caused the cells to arrest at the G2/M phase of
the cell cycle within 24 hours (see FIG. 7). At higher doses a
significant fraction of the tumor cells undergo apoptosis
within 24 hours, as assessed by Annexin Vassay (see FIG. 8).
Although the compounds, compositions, and methods

(I)

described herein have been described in connection with

Some variations and/or embodiments, it is not intended to be

limited to the specific form set forth herein. Rather, the scope
of the methods described herein is limited only by the claims.
Additionally, although a feature may appear to be described
in connection with particular variations, one skilled in the art
would recognize that various features of the described varia
tions and/or embodiments may be combined in accordance

R
25

R10

N

s
K.

-

R11

N

o

R6 R7

30

(R12)

with the methods described herein.

Although individual features of the compounds, composi
tions, and methods described herein may be included in dif
ferent claims, these may be advantageously combined, and
the inclusion in different claims does not imply that a com
bination of features is not feasible and/or advantageous. Also,
the inclusion of a feature in one category of claims does not
imply a limitation to this category, but rather the feature may
be equally applicable to other claim categories, as appropri
ate. Where a compound, composition, or method comprises
one or more specified items or steps, others can also be
included. The invention also contemplates, however, that the
described compounds, compositions, or methods may be
used without other items or steps and thus it includes the
recited composition or process consisting of or consisting
essentially of the recited items, materials or steps, as those
terms are commonly understood in patent law.
Terms and phrases used in this document, and variations
and/or embodiments thereof, unless otherwise expressly
stated, should be construed as open ended as opposed to
limiting. As examples of the foregoing: the term “including
should be read to mean “including, without limitation' or the
like; the terms “example' or “some variations” are used to
provide exemplary instances of the item in discussion, not an
exhaustive or limiting list thereof, and adjectives such as

(II)

R

O

40

1n

R. R.
R

-N "k
R

\ X-N
R

R 14

R8

R. R.

N

RN1S2
N
7

N-Q

N R5

(R12)pi

m

R.13
R

15

R 16

(III)
R9
45

R2 R3
=N

Sk R4

R 14

R10 \ X-N N-Q
Y K R8
R11 N R.
50

N

/=
I6
R16 V /
N. R17
N

R15

wherein m is 0 or 1;
55

“conventional,” “traditional,” “normal,” “standard,” “known

and terms of similar meaning should not be construed as
limiting the item described to a given time period or to an item
available as of a given time, but instead should be read to
encompass conventional, traditional, normal, or standard
technologies that may be available or known now or at any
time in the future. Likewise, a group of items linked with the
conjunction “and” should not be read as requiring that each
and every one of those items be present in the grouping, but
rather should be read as “and/or unless expressly stated
otherwise. Similarly, a group of items linked with the con

R9

35

60

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6
ring atoms, or may be a 5-6 membered ring that is fused
with or bonded to one or more additional aryl, hetero
cyclic, or heteroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R7, and R is independently

Selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

each R, R', R'', R. R. R. R', and R' is indepen
65

dently selected from hydrogen, optionally substituted
alkyl, or optionally substituted aryl, halo, OR, NR, SR,
S(O)R, SOR, SONR, NRSOR, NRCONR,

US 8,609.672 B2
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17. The compound of embodiment 16, wherein W is
selected from the group consisting of:

NRCOOR, NRCOR, CN, COOR, CONR, OOCR,

COR, CH(OH)R, and NO, wherein each R is indepen
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het
eroalkynyl,

C3-C8

heterocyclyl,

C4-C10

heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl,
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and
wherein each R is optionally substituted, with the pro

viso that R' for formula (I) must not be hydrogen; and
each R'' is independently selected from hydrogen or
optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of embodiment 1, which is a compound
of formula (I) or a pharmaceutically acceptable salt thereof.
3. The compound of embodiment 1, which is a compound
of formula (II) or a pharmaceutically acceptable salt thereof.
4. The compound of embodiment 1, which is a compound
of formula (III) or a pharmaceutically acceptable salt thereof.
5. The compound of any of embodiments 3-4, wherein Q is

10

15

(R2)

C O.

wherein each R' is independently selected from the group

6. The compound of any of embodiments 1-5, wherein each

R", R. R. R. R. R. R', and Rishydrogen.
7. The compound of any of embodiments 1-6, wherein each
RandR'' is independently selected from hydrogen, option

25

ally substituted alkyl, optionally substituted aryl, halo, OR,
NRSR, CN, COOR, CONR, COR, CH(OH)R, and NO.
8. The compound of any of embodiments 1-7, wherein each

R" is independently selected from optionally substituted

alkyl, optionally substituted aryl, halo, OR, NR, SR, CN,
COOR, CONR, COR, CH(OH)R, and NO.
9. The compound of any of embodiments 1-8, wherein each

consisting of hydrogen, optionally Substituted alkyl,
optionally substituted aryl, halo, OR, NR, SR, CN,
COOR, CONR, COR, CH(OH)R, and NO.
18. The compound of embodiment 17, wherein W is
selected from the group consisting of:

30

R" is independently selected from optionally substituted

alkyl or optionally substituted aryl.
10. The compound of any of embodiments 1-9, wherein

35

each R" is -(CH2). Ar, wherein p is 1-2 and Aris option

ally substituted phenyl.
11. The compound of any of embodiments 1-10, wherein

each R and R'' is hydrogen and each R' is optionally sub

stituted alkyl.
12. The compound of any of embodiments 1-11, wherein

40

each R" is independently selected from methyl, ethyl, pro

pyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
neopentyl, and benzyl.
13. The compound of any of embodiments 1-12, wherein

45

each R' is independently selected from optionally substi

tuted ethyl or benzyl.
14. The compound of any of embodiments 1-13, wherein

each R" is independently selected from optionally substi

tuted alkyl, optionally substituted aryl, halo, OR, NR, SR,
CN, COOR, CONR, COR, CH(OH)R, and NO.
15. The compound of any of embodiments 1-14, wherein

50

each R'' is hydrogen.

16. The compound of any of embodiments 1-15, wherein
W in any compound having formula (I), (II), or (III) is:

55

20. The compound of any of embodiments 1-15, wherein
W in any compound having formula (I), (II), or (III) is:

60

65

wherein each A, B, C, and D is independently NorCR' in
any combination.

wherein X and Y are N or CR':
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Z is selected from the group consisting of NR", O, and S;

24. The compound of embodiment 23, wherein W is

and

selected from the group consisting of:

R’ is hydrogen or R''.
21. The compound of embodiment 20, wherein W is s

selected from the group consisting of:

N---

N--- W

#

-

N

M

N--- ',

...

-

N---,

N

----&----

}=

)
N

Nn-NH

N

Vvvvr

and

O

Né

15

A.

N

Y2

and

R12

R12
N- - -

2O

N
wr:

N/

R

------- -

N

N.

=

N-S

M

O

Vvvv,

1-\

N

M

af2

R'

rivn
A.

HN

\

N

R12

-rviv
w

10

N

s

---- ----

R12
NH

2s

R

wherein each R' is independently selected from the group
consisting of hydrogen, optionally Substituted alkyl, and

optionally substituted aryl.

wherein each R'' is independently selected from the group

25. The compound of embodiment 24, wherein W is

consisting of hydrogen, optionally Substituted alkyl, and

optionally substituted aryl.

selected from the group consisting of:
30

22. The compound of embodiment 21, wherein W is
selected from the group consisting of:

N

3s
N---,

-rArr
w

}=

----s--- -

N---

N --------WVVV

rvin
F

w

N

N

wrviv

N
o

HNS a

and

A.

OS Na
N---

40

A

-

N-

N

myV

NR, N

45

1-\
N- S

M

'Ne

---

-

----&--- -

o

}=

N-NH

N

N

26. The compound of embodiment 1, wherein the com
pound is:
50

N

23. The compound of any of embodiments 1-15, wherein

R10

W in any compound having formula (I), (II), or (III) is:

-

Vvvv,

N

wr:

s

60
2O

selected from the group consisting of NR',
s

12

V

N

N

/

\

N:

(R2)

XN Y27.

with

N N/

/

NW

wherein R'O is selected from the group consisting of
optionally substituted alkyl and optionally substituted
aryl;

and wherein each R" is independently selected from the
65

group consisting of hydrogen, optionally Substituted

Y and Z are N or CR'?; and

alkyl, optionally substituted aryl, halo, OR, NR, SR,

R’ is hydrogen or R''.

CN, COOR, CONR, COR, CH(OH)R, and NO.
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31. The compound of embodiment 30, wherein the com
pound is:

57
27. The compound of embodiment 26, wherein the com
pound is:

=N

/ \

N

\ -( )

=N

O

A

R -(- N

\

N -

O

N

10

28. The compound of embodiment 1, wherein the com
pound is:

O

/

15

32. The compound of embodiment 1, wherein the com
pound is:

N

N

O

R- NX-N\ /N

3-y
- SS (R):

NH

/ v

25

NH

y

PS(R2)

wherein R' is selected from the group consisting of
optionally substituted alkyl and optionally substituted
aryl;

and wherein each R'' is independently selected from the

group consisting of hydrogen, optionally substituted
alkyl, optionally substituted aryl, halo, OR, NR, SR,
CN, COOR, CONR, COR, CH(OH)R, and NO.
29. The compound of embodiment 28, wherein the com
pound is:

=N

/-

O

\ NX-N\ /N

/ N

N

wherein R' is selected from the group consisting of
30

optionally substituted alkyl and optionally substituted
aryl;

and wherein each R" is independently selected from the

35

group consisting of hydrogen, optionally Substituted
alkyl, optionally substituted aryl, halo, OR, NR, SR,
CN, COOR, CONR, COR, CH(OH)R, and NO.
33. The compound of embodiment 32, wherein the com
pound is:

40
W.

N

/

\

N

\ /

/-(-O

NH

O

45

30. The compound of embodiment 1, wherein the com
pound is:
/

\

R-(-O

O

: y HNy \N-yy
\/
(R2)

sy

NH

50

N

/ R.
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34. A pharmaceutical composition comprising a com
pound according to any of embodiments 1-33 and at least one
pharmaceutically acceptable excipient.
35. The use of a compound according to any of embodi
ments 1-33 to manufacture a medicament.

36. The method of embodiment 35, wherein the medica

ment is a medicament for the treatment of a proliferative
disorder.

37. A method to identify a molecule that modulates protein

wherein R' is selected from the group consisting of 60 kinase activity, said method comprising screening a com

pound according to any of embodiments 1-33, to identify a
compound having an effect on the activity of a protein kinase.
and wherein each R" is independently selected from the
38. A method to treat a proliferative disorder, said method
group consisting of hydrogen, optionally substituted 65 comprising administering to a Subject in need of Such treat
alkyl, optionally substituted aryl, halo, OR, NR, SR, ment, an effective amount of a compound of formula (I), (II),
CN, COOR, CONR, COR, CH(OH)R, and NO.
or (III):
optionally substituted alkyl and optionally substituted
aryl;
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41. A method to reduce cell proliferation, said method
comprising administering to a cell in an in vitro or in vivo
environment, an effective amount of a compound of formula
(I), (II), or (III):

(I)

(I)
R11

R

R6 R7

N
10

(R12)

N

(II)

R9

R

N

R10 \ X-N
R11

N

1S

R. R.
R

7

R

R 14

N-Q

21

N

Y K
R5 R6 R7 R8

(R12)
(II)

(R12)pi

)m
15

R9

R 16

R10 \ X-N

R

EN

R10 \
R11

y-N

N Rs

R
R 14

N-Q

R16W /

R7 R R13

R. R.

R.13
15

R 16

(III)
2
(R');

R9

YR 7

30

R

R10 \ X-N
R11

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6
ring atoms, or may be a 5-6 membered ring that is fused
with or bonded to one or more additional aryl, hetero
cyclic, or heteroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R7, and R is independently

heterocyclyl,

40

45

2

(R');

YR 7

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6
ring atoms, or may be a 5-6 membered ring that is fused
with or bonded to one or more additional aryl, hetero
cyclic, or heteroaryl rings;
each Q is CH, SO, or C=O;
each R', R. R. R. R. R. R7, and R is independently
Selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

each R, R', R'', R12, R', R', R', and R' is indepen

dently selected from hydrogen, optionally substituted
alkyl, or optionally substituted aryl, halo, OR, NR, SR,
S(O)R, SOR, SONR, NRSOR, NRCONR,
NRCOOR, NRCOR, CN, COOR, CONR, OOCR,
COR, CH(OH)R, and NO, wherein each R is indepen
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het

50

eroalkynyl,

55

C3-C8

heterocyclyl,

C4-C10

heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl,
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and
wherein each R is optionally substituted; and

each R'7 is independently selected from hydrogen or
60

Subject.

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.

42. The method of embodiment 41, wherein the cell is a

40. The method of embodiment 39, wherein the cancer is

selected from the group consisting of leukemia, non-Small
cell lung cancer, colon cancer, central nervous system (CNS)
cancer, melanoma, ovarian cancer, renal cancer, prostate can

R16W /

R13

wherein m is 0 or 1;

each R'7 is independently selected from hydrogen or
tive disorder is a tumor or a cancer in a human or animal

N

/=

N

R15

C4-C10

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.
39. The method of embodiment 38, wherein the prolifera

N Rs R6 R7S.R

35

each R. R. R'', R. R. R. R', and R' is indepen

heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl,
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and
wherein each R is optionally substituted; and

R 14

N-Q

N

Selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;
dently selected from hydrogen, optionally substituted
alkyl, or optionally substituted aryl, halo, OR, NR, SR,
S(O)R, SOR, SONR, NRSOR, NRCONR,
NRCOOR, NRCOR, CN, COOR, CONR, OOCR,
COR, CH(OH)R, and NO, wherein each R is indepen
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het

R2 R3

=N

wherein m is 0 or 1;

cer, and breast cancer.

(R12)pi

m

R

N

C3-C8

N

R8

25

/=

R 15

eroalkynyl,

R 14

N

21

N

Sos

R

N

7

RN

N-Q

N R5

R2 R3

1n

R. R.
R

R

EN

(III)
R9

R8

R6 R7

15

R13
R

R5

R11

N
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cancer cell, and wherein the cancer is selected from the group
consisting of leukemia, non-Small cell lung cancer, colon
cancer, central nervous system (CNS) cancer, melanoma,
ovarian cancer, renal cancer, prostate cancer, and breast can
C.

US 8,609.672 B2
61
43. A method to induce cell death, said method comprising
administering to a cell in an in vitro or in vivo environment, an
effective amount of a compound of formula (I), (II), or (III):

62
44. The compound of embodiment 1, wherein one or more

R. R', R' or R'' are independently halo.
45. The compound of embodiment 44, wherein each R" is
bromo.
46. The compound of embodiment 44, wherein each R' is
fluoro.

47. The compound of any of embodiments 44-46, wherein
the compound is:

(I)
10

R11

N-y

n-()-O

R6 R7

\ /

15

(R12)
(II)

R9
N

R. R.
R

R

R10 \ X-N
R11

N

1n
7

RN

R 14

N-Q

N

Y K

R5 R6 R7 R8

)m

48. The compound of any of embodiments 44-46, wherein
the compound is:

N

21
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R13
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R 16
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N

N

N

(III)
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N
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We claim:

1. A compound of formula (I):
(I)
40

"Sk"N W -\
X-N

wherein m is 0 or 1;

N

each n is independently 0-6:
each W represents an optionally substituted aryl or het
eroaryl ring, which may be a monocyclic group with 5-6
ring atoms, or may be a 5-6 membered ring that is fused
with or bonded to one or more additional aryl, hetero
cyclic, or heteroaryl rings;
each Q is CH, SO, or C=O;

each R', R. R. R. R. R. R7, and R is independently

Selected from hydrogen, optionally Substituted alkyl, or
optionally substituted aryl;

R10

eroalkynyl,

C3-C8

heterocyclyl,

optionally substituted alkyl;
or a pharmaceutically acceptable salt thereof.

R5

R8

o

R6 R7
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wherein

55

n is independently 0-6:
W represents an optionally substituted aryl or heteroaryl
ring, which may be a monocyclic group with 5-6 ring
atoms, or may be a 5-6 membered ring that is fused with
or bonded to one or more additional aryl, heterocyclic, or
heteroaryl rings;

each R', R. R. R. R. R. R', and R is independently
60

Selected from hydrogen, optionally Substituted alkyl, or
optionally Substituted aryl; and

each R. R', R'', and R' is independently selected from

C4-C10

heterocyclyclalkyl, C6-C10 aryl, C5-C10 heteroaryl,
C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, and
wherein each R is optionally substituted; and

each R'' is independently selected from hydrogen or

R11

(R12)

each R. R. R'', R. R. R. R', and R' is indepen

dently selected from hydrogen, optionally substituted
alkyl, or optionally substituted aryl, halo, OR, NR, SR,
S(O)R, SOR, SONR, NRSOR, NRCONR,
NRCOOR, NRCOR, CN, COOR, CONR, OOCR,
COR, CH(OH)R, and NO, wherein each R is indepen
dently H, C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alk
enyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 het

N / Y-K
N

45

N
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hydrogen, optionally Substituted alkyl, or optionally
substituted aryl, halo, OR, NR, SR, S(O)R, SOR,
SONR, NRSOR, NRCONR, NRCOOR, NRCOR,
CN, COOR, CONR, OOCR, COR, CH(OH)R, and
NO, wherein each R is independently H, C1-C8 alkyl,
C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalk
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enyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C3-C8 het
erocyclyl, C4-C10 heterocyclyclalkyl, C6-C10 aryl,
C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 het
eroarylalkyl, and wherein each R is optionally substi

64
5. The compound of claim 4, wherein the compound is:

tuted, with the proviso that R' must not be hydrogen;
or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R' is independently
selected from optionally substituted alkyl, optionally substi
tuted aryl, halo, OR, NR, SR, CN, COOR, CONR, COR,
CH(OH)R, and NO.

10

6. The compound of claim 1, wherein the compound is:

3. The compound of claim 1, wherein each R" is indepen

dently selected from optionally substituted alkyl, optionally
substituted aryl, halo, OR, NR SR, CN, COOR, CONR,
COR, CH(OH)R, and NO.
4. The compound of claim 1, wherein the compound is:

=N

/ V

15

N-y

Br / V / \,

-(-)- \ /

\ /

V
7. A pharmaceutical composition comprising a compound
of claim 1 and at least one pharmaceutically acceptable
excipient.
8. A method to inhibit a tyrosine kinase of a platelet derived
growth factor receptor (PDGFR) comprising administering a
pharmaceutical composition comprising a compound or salt

(R2)

wherein R' is selected from the group consisting of
optionally substituted alkyl and optionally substituted
aryl;

and wherein each R" is independently selected from the

group consisting of hydrogen, optionally substituted
alkyl, optionally substituted aryl, halo, OR, NR, SR,
CN COOR, CONR, COR, CH(OH)R, and NO.

of claim 1.
30

9. The method of claim 8, wherein the tyrosine kinase of
the platelet derived growth factor receptor (PDGFR) is
selected from the group consisting of PDGFRC, PDGFRB,
KIT, Flt3, and CSF1R.
k

k

k

k

k

